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Abstract
Background: It is a commonly accepted belief that cancer cells modify their transcriptional state during the progression of
the disease. We propose that the progression of cancer cells towards malignant phenotypes can be efficiently tracked using
high-throughput technologies that follow the gradual changes observed in the gene expression profiles by employing
Shannon’s mathematical theory of communication. Methods based on Information Theory can then quantify the divergence
of cancer cells’ transcriptional profiles from those of normally appearing cells of the originating tissues. The relevance of the
proposed methods can be evaluated using microarray datasets available in the public domain but the method is in principle
applicable to other high-throughput methods.
Methodology/Principal Findings: Using melanoma and prostate cancer datasets we illustrate how it is possible to employ
Shannon Entropy and the Jensen-Shannon divergence to trace the transcriptional changes progression of the disease. We
establish how the variations of these two measures correlate with established biomarkers of cancer progression. The
Information Theory measures allow us to identify novel biomarkers for both progressive and relatively more sudden
transcriptional changes leading to malignant phenotypes. At the same time, the methodology was able to validate a large
number of genes and processes that seem to be implicated in the progression of melanoma and prostate cancer.
Conclusions/Significance: We thus present a quantitative guiding rule, a new unifying hallmark of cancer: the cancer cell’s
transcriptome changes lead to measurable observed transitions of Normalized Shannon Entropy values (as measured by
high-througput technologies). At the same time, tumor cells increment their divergence from the normal tissue profile
increasing their disorder via creation of states that we might not directly measure. This unifying hallmark allows, via the the
Jensen-Shannon divergence, to identify the arrow of time of the processes from the gene expression profiles, and helps to
map the phenotypical and molecular hallmarks of specific cancer subtypes. The deep mathematical basis of the approach
allows us to suggest that this principle is, hopefully, of general applicability for other diseases.
Citation: Berretta R, Moscato P (2010) Cancer Biomarker Discovery: The Entropic Hallmark. PLoS ONE 5(8): e12262. doi:10.1371/journal.pone.0012262
Editor: William C S Cho, Queen Elizabeth Hospital, Hong Kong
Received December 13, 2009; Accepted June 26, 2010; Published August 18, 2010
Copyright:  2010 Berretta, Moscato. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors acknowledge the support of the Australian Research Council (ARC) Centre of Excellence in Bioinformatics, Hunter Medical Research
Institute, The University of Newcastle, and ARC Discovery Projects DP0559755 (Evolutionary algorithms for problems in functional genomics data analysis) and
DP0773279 (Application of novel exact combinatorial optimisation techniques and metaheuristic methods for problems in cancer research). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Pablo.Moscato@newcastle.edu.au
Introduction
In a seminal review paper published nine years ago, Hanahan
and Weinberg [1] introduced the ‘‘hallmarks of cancer’’. They are six
essential alterations of cell physiology that generally occur in
cancer cells independently of the originating tissue type. They
listed: ‘‘self-sufficiency in growth signals, insensitivity to growth-inhibitory
signals, evasion of the normal programmed-cell mechanisms (apoptosis),
limitless replicative potential, sustained angiogenesis, and finally, tissue
invasion and metastasis’’. More recently, several researchers have
advocated including ‘‘stemness’’ as the seventh hallmark of cancer
cells. This conclusion has been reached from the outcomes of the
analysis of high-throughput gene expression datasets [2,3]. The new
role of stemness as a hallmark change of cancer cells is also
supported by the observation that histologically poorly differen-
tiated tumors show transcriptional profiles on which there is an
overexpression of genes normally enriched in embryonic stem
cells. For example, in breast cancer the activation targets of the
pluripotency markers like NANOG, OCT4, SOX2 and c-MYC
have been shown to be overexpressed in poorly differentiated
tumors in marked contrast with their expression in well-
differentiated tumors [4].
Other authors suggest different hallmarks, with many papers
pointing alternative processes as their primary focus of their
research. The difference may stem from the fact that these authors
prefer to cite as ‘‘key hallmarks’’ physiological changes which occur
at a ‘‘lower level’’ scale closer to the molecular events. These
authors cite, for example, ‘‘mitochondrial dysfunction’’ [5,6] (including,
but not limited to ‘‘glucose avidity’’ [7] and ‘‘a shift in glucosemetabolism
from oxidative phosphorylation to glycolysis’’ [6,8], ‘‘altered glycolysis’’ [9],
‘‘altered bioenergetic function of mitochondria’’ [10]), ‘‘dysregulation of cell
cycle and defective genome-integrity checkpoints’’ [11], ‘‘aberrant DNA
methylation’’ [12] (‘‘promoter hypermethylation of hallmark cancer genes’’
[13] and ‘‘CpG island hypermethylation and global genomic hypomethyla-
tion’’ [14]), ‘‘shift in cellular metabolism’’ [15,16,17], ‘‘regional hypoxia’’
[18], ‘‘microenviroment acidosis’’ [19], ‘‘abnormal microRNA regulation’’
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‘‘disruption of cellular junctions’’ [27], ‘‘avoidance of the immune response’’
[28], ‘‘pre-existing chronic inflammatory conditions’’ [29,30], ‘‘cancer-
related inflammation’’ [29], ‘‘disabled autophagy’’ [28], ‘‘impaired cellular
senescence’’ [31], ‘‘altered NF-kappaB signalling’’ [32], ‘‘altered growth
patterns, not altered growth per se’’ [33], ‘‘disregulated DNA methylation and
histone modifications’’ [34], ‘‘tissue dedifferentiation’’ [35,36], and
‘‘somatically heritable molecular alterations’’ [37]. This research enriches
the list of the most important cancer hallmarks. However, these
physiological changes occur at a ‘‘lower’’ molecular level they are
likely related sub events of the orginial seven instead of newly
discovered ‘‘key hallmarks’’. More recently, Luo et al attempted a
‘‘stress-based’’ description of some of the hallmarks in terms of
‘‘stresses’’ (‘‘DNA damage/replication stress, proteotoxic stress, mitotic stress,
metabolic stress, and oxidative stress’’) [38]. While this is an interesting
descriptive grouping, it is still a phenotypical characterization.
What is needed is a higher level unifying genotypical character-
ization, from which individual disregulated processes can be
identified in a quantitative way using the existing high-throughput
data capture methodologies. It is clear that a unifying hallmark is
needed if we aim at quantifying the cell’s progression. It is then
evident for us that a unifying mathematical formalism is necessary
to uncover the cell transcriptome’s progression from a normal to a
more malignant phenotype.
We start our quest assuming an implicit working hypothesis
common to many research groups around the world: the macroscopic
physiological changes (i.e. Hanahan and Weinberg’s ‘‘hallmarks’’) must also
correlate with global alterations of the molecular profiles of gene transcription.
It is also assumed that the ‘‘hallmark changes’’ occur along a certain
timeline, but that some of the sub-processes discussed before are
concurrent. These processes may start in a slow incremental way
with some of the major changes being early events while others
(e.g. tissue invasion and metastasis) are likely later processes
triggered by new events during cancer progression. The timeline is
not explicit and it is also likely that cancer subtypes progress to
similar timelines. In some cases the sequence of events are better
understood (e.g. some leukaemia subtypes [39]). The elicitation
and regulation of molecular events is likely to be an ongoing quest
during this century for many types of cancer.
It is not to be assumed that some of the transitions of the
transcriptome are gradual. That is a hypothesis that is unnecessary
in this study. We envision that the progression of cancer may have
‘‘switches’’, with a number of concurrent converging events leading
to macroscopic observable changes in the gene expression profile
resulting in dramatic variations of expression patterns. For
instance, these molecular switches could not be characterized by
an ‘‘oncogene’’ but by a large number of the genes that have
changed its transcriptional state. These abrupt changes may be
triggered by the confluence of several non-linear interactions, and
are likely to be related to the physiological hallmarks we refer to
above.
The presence of macroscopic observable changes that are
computable from a large number of relatively smaller changes
mean that it may be possible to find an objective mathematical formalism to
infer the turning point at which these radical changes occur.
It is then evident that computing the Jensen-Shannon divergences,
the Normalized Shannon Entropy, and the Statistical Complexity of
samples reveal different global transcriptional changes. It is,
however, not easy to infer if these changes would correlate with a
gradual progression or sudden changes. However, one valid
mathematical possibility is that the most important ‘‘hallmark of
cancer’’, a unifying principle above all, is the existence of a
measurable gradual ‘‘progression’’ from a well-differentiated gene
expression profile (corresponding to a healthy tissue). This would
reveal the timeline of a higher level process that is observable and
measurable via a change of Normalized Shannon Entropy and an
increment of Jensen-Shannon divergences from the originating tissue
type. If this is the case, by correlating the changes in Information
Theory quantifiers with the expression of the genes we would be
able to not only uncover useful biomarkers to track this
progression but to explain the ‘‘hallmarks’’ in an ordered timeline.
The timeline also yields clinical and translational important
outcomes. Such analytical methodology will naturally produce ‘‘a
continuous staging’’ of the cancer samples, based on a solid
foundations of Information Theory, based on the knowledge of
transcriptional profile of healthy cells as reference to measure
divergences. In addition, as a mathematical methodology, it can be
applied to other high-throughput technologies for which a probability
distribution function of observed abundances has been computed.
With these ideas in mind, we provide a ‘‘transcriptomic-driven’’
method revealing important biomarkers for cancer progression a
direction of time for which they are presented. The method,
however, is generalizable to other type of high-throughtput techonologies
(e.g. proteomic studies). We have chosen two types of cancers to
study which are almost at the antipodes in terms of progression
rates: prostate cancer and melanoma.
Prostate cancer progresses very slowly. Pathological samples are
common in autopsies of men as young as 20 years old. By the age
of 70 more than 80% of men have these alterations, a fact that
already shows a relationship of this cancer type with increasing
age. The clinical management of prostate cancer requires the
identification of the so-called Gleason patterns in the biopsies [40],
which after almost fifty years is still ‘‘the sole prostatic carcinoma grading
system recommended by the World Health Organization’’. However,
undergrading, underdiagnosis, interobserver reproducibility and
variable trends in grading have been observed as major problems
[41,42]. Melanoma, on the other hand, differs from prostate
cancer in its rapid progression [43] and it is considered one of the
most aggressive types of cancer. One of melanoma’s usual markers
of progression and concern (i.e thickness) is measured in
millimetres, which gives a rough idea of how devastatingly fast
the disease can spread.
We will present our results starting with one prostate cancer
dataset, followed by another in melanoma, to come back to the
prostate cancer discussion using another highly relevant dataset.
This is a departure from the alternative approach in which each
disease is discussed in separate sections. However, after consider-
ing several possibilities, we are convinced that our approach is the
most appropriate to showcase the technique and its power. Details
on the datasets and methods used are given in the ‘Materials and
Methods’ section of this paper. We also refer to the original studies
and manuscripts associated to the three datasets we analysed.
Results
Prostate Cancer – Lapointe et al.’s dataset (File S1)
The first dataset is the one from Figure one in Lapointe et al.
[44]. This data is available from http://microarray-pubs.stanford.
edu/prostateCA/images/fig1data.txt and supplemen-tary materi-
al is also available from http://microarray-pubs.stanford.edu/
prostateCA/.
In the original study, the authors used a cDNA microarray
technology that allowed them to measure gene expression of several
thousand genes on 112 samples, including 41 normal prostate
specimens, 62 primary prostate tumours and 9 lymph node
metastases. From that set, a subset of 5,153 probes were selected
as differentiating prostate cancer samples from normal and
metastases (this is the set from figure one in Lapointe et al. [44]
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missing values, we first calculated the Normalized Shannon Entropy and
the MPR-Statistical Complexity for the each sample.
The flowing section explains the context in which our results
were generated (refer to the ‘Materials and Methods’ section for
detail on how our quantities are computed). The Normalized
Shannon Entropy measure is widely used in ecosystem modelling to
quantify species diversity, where it is acknowledge as having great
sensitivity to relative abundances of species in an ecosystem [45].
We utilise the same sensitivity to differentiate a samples in cancer
datasets. Figure 1 shows that the Normalized Shannon Entropy of
prostate cancer tumor samples do not differ much from normal
samples. This is in contrast to lymph node metastasis samples that
appear to have smaller values of Normalized Shannon Entropy.
A mathematical interpretation of this result is that the samples
from lymph node metastases have cells that not only varied their
transcriptomic profile, they have also ‘‘peaked’’ the distribution of
expression values with significant fold increases on a smaller
number of probes. This explains the reduction in Normalized
Shannon Entropy. We note that there are several mechanisms that
can explain a macroscopically observable global reduction of
transcription. For instance, this may indicate that a relatively large
number of genes have reduced their expression levels by genome
damage, changes in gene regulation, or other silencing processes.
It is reassuring to observe that the changes of the most prototypical
quantitative measure we can draw from Information Theory, the
Normalized Shannon Entropy correlate well with the transition
between normal samples with to ones with metastases. However,
it is also evident from that normal samples do not differentiate
much from the tumor group (the Normalized Shannon Entropy values
do not differ much). It is then not the number of genes with high
expression values, but the change in the distribution of expression
levels on the molecular profile, that can provide the other measure
that could distinguish these other samples. This must be handled
by the other statistical complexity measures to be discussed next.
Several statistical complexity measures can be defined which
aim to clarify our argument. We will first discuss the results of
computing the MPR-Statistical Complexity measure (in the previous
figure the y-coordinates correspond to the MPR-Statistical Complexity
values of each sample). The MPR-Statistical Complexity is propor-
tional to both the Normalized Shannon Entropy associated to the
transcription profile and the Jensen-Shannon’s divergence between that
probability density function and the uniform probability distribu-
tion. Again, we refer the reader to the ‘Materials and Methods’
section for an explanation of how these magnitudes are computed.
Although the results of using the MPR-Statistical Complexity might
not seem particularly impressive, there are a few reasons why we
introduce them at this stage. We want to illustrate a fact that can
already be observed when we employ this measure on this dataset.
In this dataset, for a given entropy value interval, normal tissue
samples tend to have relatively lower MPR-Statistical Complexity
values than tumor and lymph node metastasis. This means that
both prostate cancer and metastases samples diverge from a ‘‘more
uniform’’ distribution indicating that the distribution ‘‘peaks’’ in
fewer active genes. It also means that, in terms of Jensen-Shannon’s
divergence, the transcriptional profile of a normal prostate cell
sample is ‘‘closer’’ to a uniform distribution than to the one that is
observed in a prostate cancer cell sample.
The reader will readily argue, and with reason, that the
transcriptional profile of a normal cell is tissue-specific and that it
hardly resembles that of a uniform distribution of expression
values. That is correct and this observation motivates the
introduction of two new statistical complexity measures. We
generically call these two variants as ‘M-complexities’ (with ‘M’
standing for ‘‘modified’’). They have the same functional form as the
MPR-Statistical Complexity, but instead of computing the Jensen-
Shannon’s divergence from a uniform probability distribution we
compute it against an ad hoc probability distribution functions
derived from the data. In this sense, these measures are more
supervised then the MPR-Statistical Complexity is. Another perspec-
tive is that the MPR-Statistical Complexity is a special case of this
measure in which the ad hoc probability distribution function of
reference is the equiprobability distribution. The relevance of this
measure derives from being a general definition that allows
Figure 1. The Normalized Shannon Entropy and the MPR-Statistical Complexity for each of the 112 samples in Lapointe et al. [44].
Metastatic samples have typically lower values of Normalized Shannon Entropy than normal samples and prostate cancer primary tumors. The
reduction in Normalized Shannon Entropy indicates that there exists a significant reduction on the expression of a large number of genes, or that the
gene profile of metastatic samples has a more ‘‘peaked’’ distribution (due to the upregulation of a selected subset of genes). Both possibilities just
cited are not mutually exclusive. We also note that neither the Normalized Shannon Entropy, nor the MPR-Statistical Complexity (as a single
unsupervised quantifier), can help differentiate between tumor and normal samples, indicating that other Information Theory quantifiers are required
for this discrimination.
doi:10.1371/journal.pone.0012262.g001
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measure divergences to the ‘‘initial’’ and ‘‘final’’ transcriptomic
states (two states of reference). Taken as computed averages over
normal samples, and respectively metastatic ones, these measures
will allow tracking the processes of differentiation of a cancer cell
from a particular tissue type.
For example, using Lapointe et al.’s dataset, the M-Normal
statistical complexity quantifier first requires the computation of
the probability distribution function of the average gene expression
profile of all normal prostate samples. Afterwards, the Normalized
Shannon Entropy and the Jensen-Shannon’s divergence of any sample
profile will be computed using the divergence to that averaged
normal distribution. Analogously, we compute the M-Metastases
statistical complexity quantifier by first calculating the average
profile of the metastases samples, and then generating the
corresponding probability distribution function, finally computing
the Jensen-Shannon’s divergence with that profile. We refer to the
‘Materials and Methods’ section for details of the calculations.
The results can be observed in Figure 2. On the x-axis, the
lymph node metastases have the largest values of M-Normal
indicating a divergence from the normal profile. In addition, the
M-metastases values of normal samples tend to be higher than most
of the metastasis samples (with the exception of only one).
Figure 2 shows a gradual progression of the samples positions on
this plane from a well-differentiated tissue type specific profile, first
to a more heterogeneous primary tumor cluster, and finally to an
even less differentiated metastatic profile.
The result presented in Figure 2 shows that the prostate cancer
samples, which are not metastases and therefore could have been
scattered anywhere on the plane, are clustered on a particular
confined area between the two other groups. We understand that
there are reasons to be sceptical about this result being not just a
simple consequence of the gene selection process used by Lapointe
et al. For example, if we assume that the 5,153 probes singled out by
Lapointe et al. in their figure one of Ref. [44] (and that constitute
our original data) have been selected with a supervised method
that try to distinguish between normal and metastases, then the
relative position of normal and metastases samples is perhaps
something to be expected. However, even under that assumption,
what is not expected is the position of all primary tumor prostate
cancer samples, linking the normal cluster of samples with the
metastases one. Note that the definition of both the M-Normal and
M-Metastases measures do not use any information from the
primary tumor prostate cancer samples, so the location of these
samples between the normal cluster and the metastases, bridging
them naturally is something to highlight. Together with Figure 1,
it gives evidence that supports the working hypothesis that a
gradual ‘‘progression’’ occurs, from the normal tissue specific
profile to the metastasis one.
Indeed, following our line of argument, Figure 2 has even more
relevance when we highlight the fact that the 5,153 probes have not
been selected with a supervised method. The authors say that the only
selection criteria was to single out the 5,153 cDNAs whose
expression varied most across samples. In the supplementary notes
of their paper the authors say: ‘‘We included for subsequent analysis only
well measured genes whose expression varied, as determined by (1) signal
intensity over background .1.5-fold in both test and reference channels in at
least 75% of samples, and (2) 3-fold ratio variation from the mean in at least
two samples; 5,153 genes met these criteria.’’ As a consequence, Figure 2
has been generated without class selection bias only using the
genes that have the most varied expression pattern.
We now turn to another aspect of the statistical complexity and
entropy analysis. We note that Figure 2 shows that the metastases
samples have a clear reduction on Normalized Shannon Entropy in
comparison with the values observed for the normal samples. At
the same time, metastases samples, as expected, have higher M-
normal complexity than the normal samples (Figure 2). It is then
interesting to evaluate the value of the Jensen-Shannon divergence of
Figure 2. M-Normal against M-Metastases for the samples in Lapointe et al. [44]. We have seen in Figure 1, that the Normalized Shannon
Entropy and the MPR-Statistical Complexity differentiate the metastatic samples from the normal samples, but that these two measures can not help
to discriminate the primary tumors from the normals. We show here the results of two statistical complexity measures which are in some sense
supervised (i.e. dependent on the dataset being interrogated). We call these two stastical mesured M-Normal and M-Metastases. They have the same
functional form of the MPR-Statistical Complexity, but they use the average normal and average metastatic profile as probability distribution functions
of reference. As a consequence, the M-normal and M-metastases are directly proportional to the Jensen-Shannon divergences with the normal (and
respectively with the metastatic) gene expression profile. It is remarkable that, although we are using these end processes only (from Lapointe et al’s,
dataset of 5,153 probes6112 samples), most of the primary tumor samples appear as a transitional state between the normal and metastatic group.
This is remarkable since the primary tumor samples were not used to define the M-normal and M-metastases measures and, in principle, the samples
could have been located anywhere in the (M-normal, M-metastases)-plane. Computation of correlations of the probe expressions values can help us
identify genes which are highly correlated with a divergence from the normal expression profile and, at the same time, converge towards the average
metastatic profile.
doi:10.1371/journal.pone.0012262.g002
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variations of Jensen-Shannon divergence to quantify one of the factors
that is related to the statistical complexity changes.
We have computed the correlation of the gene expression
profile corresponding to each of the 5,123 probes. For each of the
5,123 probes, we computed both the Pearson correlation (x-axis of
Figure 3) and the Spearman correlation (y-axis of Figure 3) of each
probe profile with the Jensen-Shannon divergence having as probability
distribution of reference that of a metastasis profile (these values
are called JSM2-Pearson and JSM2-Spearman in the accompanying
Excel file provided). With this data, we have produced Figure 3, a
scatter plot of the values associated to each probe. In this figure,
there are two probes that are immediately recognizable by any
cancer researcher, and in particular for those in prostate cancer:
KLK3/PSA (Prostate Specific Antigen) and FOS.
The interpretation of these scatter plots is not immediate and
needs an introductory explanation. Each dot corresponds to one
probe of the array. For example, a dot that is very close to the
origin of coordinates (0,0) indicates a probe such that its pattern of
gene expression (across all samples) is not correlated with the
Jensen-Shannon divergence to the average profile of a metastasis
pattern. It is, in essence, a probe which is highly uninteresting in
this regard. Probes that have a high correlation, across all samples,
either positive or negative with the Jensen-Shannon divergence to the
average profile of a metastasis pattern are highly informative.
They ‘‘co-express’’ with this measure.
Although we provide in the supplementary material the
information corresponding to all probes, we will discuss just a
few of them. This will allow the reader to understand these plots
and will put our results in the perspective with current research in
prostate cancer. We particularly highlight the position of KLK3/
PSA, FOS and CCL2. To our surprise, we have found which is
perhaps the most famous biomarker in prostate cancer KLK3/
PSA (Kallikrein-related peptidase 3), probe G_914588 (correla-
tions of 20.9312 and 20.9000 respectively). FOS and KLK3/
PSA are the second and the fourth most negatively correlated
probes in this ranking of all the genes in the microarray. With
opposite signs for correlations are CDKN2D, FOXM1, and
BRCA2. The following is a discussion of a selection of probes
(highlighted in Figure 3) in the context of prostate cancer.
CDKN2D (Cyclin-dependent kinase inhibitor 2D, p19,
inhibits CDK4). One of the genes that has strong positive
correlations is CDKN2D, (Cyclin-dependent kinase inhibitor 2D,
p19, inhibits CDK4) (Pearson correlation of 0.7543, Spearman correlation
0.6833), probe G_145503. A gene that shows a positive correlation
with the divergence of a metastasis profile indicates a gene that has a
putative reduced expression on these samples. CDKN2D is a
known regulator of cell growth regulator and controls cell cycle G1
progression [46,47]. Loss of CDKN2D in cancer cells is one event
which is generally associated to a more malignant phenotype.
FOXM1. Another probe that presents positive correlations is
FOXM1 (Forkhead box M1), with Pearson correlation of 0.7039
and Spearman correlation 0.7500), probe G_564803. It has been
recently shown that the depletion of FOXM1 still allows cells to
enter mitosis but they are unable to complete cell division. As a
consequence this leads to mitotic catastrophe or endoreduplication
[48]. FOXM1 is considered a key regulator of a transcriptional
cluster which is that is essential for proper execution of the mitotic
program and the control of chromosomal stability [49].
BRCA2 - (Breast cancer 2, early onset). Another gene with
positive correlations is BRCA2 (Breast cancer 2, early onset),
probe G_193736, with Pearson correlation of 0.8161 and Spearman
correlation 0.7333). While the loss of BRCA2 function and its
consequences in prostate cancer is being reconsidered
[50,51,52,53], BRCA2 is generally regarded as a ‘‘tumor
suppressor’’, with an established role in maintaining genomic
stability via its function in the homologous recombination pathway
for double-strand DNA repair. This result is supporting its
proposed function. Loss of BRCA2 function is thus a warning
sign of the existence of error prone cell processes. In prostate
Figure 3. A scatter plot of each of the 5,123 probes of the dataset contributed by Lapointe et al. We have computed the Pearson and
Spearman correlation of each probe expression (across samples) with the Jensen-Shannon divergence of each of the samples with the average
metastasis profile (these values are called JSM2-Pearson and JSM2-Spearman in the accompanying Excel file provided). One of the clinically most
relevant markers for prostate cancer (KLK3/PSA) together with FOS, CCL2/MCP-1, SOX9 and a probe for LOC51334 (mesenchymal stem cell protein
DSC54) appear with highly negative Spearman and Pearson correlations values, indicating that they are negatively correlated with the Jensen-
Shannon divergence from the average metastatic profile. BRCA2 (highly regarded as a tumor suppressor in cancer research), FOXM1 (a putative
regulator of the mitotic program and the control of chromosomal stability [49]), and CDKN2D (a CDK4 inhibitor) in opposition with KLK3/PSA, seems
to be positively correlated. As will be seen later in the analysis of the melanoma dataset, these positive correlations with the Jensen-Shannon
divergence from the average metastatic profile indicate a possible dysregulation of these critical processes for which these genes have key roles.
doi:10.1371/journal.pone.0012262.g003
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through upregulation of MMP9 [54]. BRCA2 loss of function due
to mutations is linked to poor survival in prostate cancer [55] and
rare germline mutations have been associated with early-onset of
prostate cancer [56].
CCL2/MCP-1 (chemokine (C-C motif) ligand 2). Bone is
one of the most common sites of prostate cancer metastasis; close
to 85% of men who die of prostate cancer have bone metastasis
[57]. The successful metastatic process to bone follows from the
activation of osteoclasts with bone resorption, which in turns leads
to the release of different growth factors from the bone matrix
[58]. CCL2 has been previously reported as expressed in human
bone marrow endothelial cells; the CCL2 stimulation promotes
prostate cancer cell migration and proliferation [57,59] and it has
been proposed as a paracrine and autocrine factor for invasion
and growth of prostate cancer [60]. As a consequence of this
central role in the tumor microenvironment, CCL2 is being the
object of several studies and is included in the list of potential
targets for novel therapies [60,61,62,63,64,65,66,67,68,69].
FOS (V-fos FBJ murine osteosarcoma viral oncogene
homolog). A probe for FOS (G_811015; correlations of
20.9380 and 20.9500 computed with Pearson and Spearman)
has a similar correlation than KLK3/PSA. The high rank of FOS
was unexpected, but perhaps it is less of a surprise for some
experienced researchers in prostate cancer as its role has been
highlighted in the past [70,71,72]. Amplification of members of
the MAPK pathway was associated with androgen independent
prostate cancer, and co-expression of RAF1, ERBB2/HER2 and
c-FOS would lead to this phenotype [73].
We will not discuss in depth the known relationships between
FOS, Lamin A/C and prostate cancer. We leave this discussion
for later, as Lamin A/C will also appear in our study of the other
prostate cancer dataset studied in this paper. Lamin A/C appears
as a member of a set of genes with reduced expression for higher
grade primary prostate cancer samples (note that the current
analysis that gave FOS as a biomarker is on lymph node metastatic
samples like here). However, we would like to point out a
connection that is currently hypothesized between Lamin A/C
and FOS, the gene we have just discussed. Ivorra et al. have
recently proposed that ‘‘lamin A overexpression causes growth arrest, and
ectopic c-Fos partially overcomes lamin A/C-induced cell cycle alterations. We
propose lamin A/C-mediated c-Fos sequestration at the nuclear envelope as a
novel mechanism of transcriptional and cell cycle control’’ [74]. In addition:
‘‘c-Fos accumulation within the extraction-resistant nuclear fraction (ERNF)
and its interaction with lamin A are reduced and enhanced by gain-of and loss-
of ERK1/2 activity, respectively.’’ [75]. These novel interactions
between LMNA and FOS, their putative role in prostate cancer
metastasis and their seemingly different behaviours in prostate
cancer lymph node metastases warrant further investigation.
SOX9 (SRY (sex determining region Y)-box 9). This
transcription factor has been recently identified as having an
importat role during embryogenesis and in the early stages of
prostate development [76,77] and in testis determination [78],
processes that link SOX9 upregulation to cancer development
[79]. Basal epithelial cells do express SOX9 in a normal prostate.
While there exists no detectable expression in lumina epithelial
cells, SOX9 has already been reported as ‘‘expressed in primary
prostate cancer in vivo, at a higher frequency in recurrent prostate cancer and in
prostate cancer cell lines (LNCaP, CWR22, PC3, and DU145)’’ [80].
Wang et al., also in [80] add that: ‘‘Significantly, down-regulation of
SOX9 by siRNA in prostate cancer cells reduced endogenous AR protein levels,
and cell growth indicating that SOX9 contributes to AR regulation and
decreased cellular proliferation. These results indicate that SOX9 in prostate
basal cells supports the development and maintenance of the luminal epithelium
and that a subset of prostate cancer cells may escape basal cell requirements
through SOX9 expression.’’ An increased value of SOX9 expression in
advanced prostate cancer has been associated to tumor
progression and the epithelial-mesenchymal transition [81].
SOX9 expression has been associated with a putative subgroup
of prostate cancer [82], associated to lymph-node metastasis (as
seems to be the case in this dataset) and has a know role in
chondrogenic differentiation processes [83].
KLK3/PSA – (Kallikrein-related peptidase 3)/Prostate
Specific Antigen. To finalize our initial discussion on this
dataset, we address KLK3. The high ranking of KLK3/PSA in
our list is perhaps one of the most remarkable retrodictive
outcomes of our approach. KLK3/PSA (also known as Prostate
Specific Antigen) is a conspiquous member of our top rank list. It is
perhaps the best blood biomarker for prostate cancer screening. Its
relevance and popularity as a target of studies is so wide that it
makes unfeasible any serious attempt to uncover its relevance in
the prostate cancer literature. A search using PubMed using the
keyword ‘KLK3’ (and the other alias names of this gene) reveals a
total of 11,429 published papers. Of course, many of these
publications relate to its role for early screening, but in this study
we are uncovering its role as a tissue biomarker. Our results echoes
a recent contribution by S. Miyano’s and his collaborators [84] on
a massive meta-analysis of microarray datasets. It is also in line
with results from clinical studies that indicate that a 5-year PSA
value is useful for predicting prostate cancer recurrence. Stock et
al. recently concluded that ‘‘patients with a PSA value ,0.2 ng/mL are
unlikely to develop subsequent biochemical relapse’’. Denham et al.,
studying data from radiation-treated patients on the TROG 96.01
clinical trial, found that on 270 patients there were two distinct
‘‘PSA-signatures’’. These two different dynamical patterns
(characterized as ‘‘single exponential’’ or ‘‘non-exponential’’)
stratified the population. Those patients in the second group
(50% of the total) ‘‘had lower PSA nadir (nPSA) levels (p,.0001), longer
doubling times on relapse (p=.006) and significantly lower rates of local
(hazard ratio [HR]: 0.47, 95% confidence interval [0.30–0.75],
p=.0014) and distant failure (HR: 0.25[0.13–0.46], p,.0001), death
due to PC (HR: 0.20[0.10–0.42], p,.0001) and death due to any cause
(HR: 0.37 [0.23–0.60], p,.0001)’’ [85]. Certainly the dynamics of
PSA, now perhaps with FOS and SOX9 added to the set of
biomarkers of interest, warrant further investigation for patient
population stratification after initial treatment.
The biomarkers discussed in this section warrant further
investigation in prediction of lymph-node metastasis and clinical
management of prostate cancer [86,87,88,89,90,91,92,93,94,95,
96,97,98,99,100,101,102,103,104,105,106,107,108,109]. We refer
the reader to the Supplementary Material to have a complete list
of probes and their correlations with the Information Theory
quantifiers.
Melanoma – Haqq et al.’s dataset (File S2)
The following sections present the results that we obtained with
a melanoma dataset. Our aim is to observe if variations of the
Normalized Shannon Entropy and the statistical complexity measures,
MPR-complexity and the modified forms M-normal and M-metastases,
provide interesting results in a different disease and experimental
setting.
In this case we have selected a gene expression dataset from
Haqq et al. [110] containing information of 14,772 cDNAs in 37
samples (Figure two from the [110]). The 37 samples include 3
normal skin, 9 nevi, 6 primary melanoma and 19 melanoma
metastases. This datasets has more phenotypical characteristics for
the group of samples.
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which had an unsually high expression value on only a few
samples, in some cases on a single one. The dataset we work with
from original contributed by Haqq et al.consists of 14,737 probes.
First, we computed the Normalized Shannon Entropy and the MPR-
Statistical Complexity for each sample (refer to the ‘Materials and
Methods’ section for a detailed presentation of these calculations).
Figure 4 shows the values of these quantifiers for each sample.
We first observe an important difference between Figure 1 and
Figure 4. In this melanoma dataset, neither the use of the
Normalized Shannon Entropy nor the MPR-complexity helps to
discriminate between normal skin, nevi, primary and metastastic
melanomas. Nevertheless, we decided to present this figure for
methodological reasons. We envision that some researchers will
calculate the Normalized Shannon Entropy and MPR-complexity using
all the probes. We note that in Figure one of Haqq et al’s original
paper, the whole probe set was previously filtered by selecting
those which vary across samples, thus indicating that they may
have information about disease subtypes (although the phenotypic
types were not biasing the selection). In this case we want to
illustrate both the Normalized Shannon Entropy and MPR-complexity
calculated using all the probes does not give the expected benefits.
We will now see the benefits of using the M-complexities.
As we did for prostate cancer (see Figure 2), we aim at
identifying if the use of the modified forms of the statistical
complexity (the M-complexities) could give some insight where the
Normalized Shannon Entropy and MPR-complexity measures fail. To
compute the M-normal measure, we need to define the average
gene expression profile for a normal cell (which we call Pave). We
thus resort to the three normal skin profiles and we produce the
average based on these profiles (details for computing the average
profiles are given in the ‘Materials and Methods’ section). We call
M-skin the resulting measure that relies on this profile. Analo-
gously, we need to compute a pattern for M-metastasis, and we
proceed to calculate the Pave profile averaging over the 19
metastases samples. The result is encouraging, as samples plotted
in the (M-skin, M-metastasis)-plane cluster in groups, showing an
important M-skin complexity transition between normal skin cells
and nevi. Most importantly, this method naturally shows that
some of the metastatic samples have a large value of M-skin
complexity, so we present the results of another experiment, aimed
at clarifying this fact.
In their original publication, Haqq et al. classified the
melanoma metastases in two groups due to their molecular
profiles: five samples were classified as ‘Type I’ and fourteen as
‘Type 2’ based on a hierarchical clustering approach. Our result
reinforced the view that the Type II melanomas metastasis is a
pretty homogeneous group, we will present the results on the (M-
skin, M-metastasis I)-plane. This means that now the Pave profile will
not be obtained by averaging over the 19 metastases samples, but
instead using only the 14 samples which have been labelled as
‘Type II’. As such, we aim at revealing if Type I samples are
indeed different in this plane, and if other clusters are also present.
Figure 5 presents the results. The first fact worth commenting is
the pronounced gap between normal skin samples and the nevi,
primary, and metastatic melanoma samples as revealed by the M-
skin measure. Note also that the M-skin is based on the average
profile that of the normal samples, which indicates that no
information about the profiles of metastasis are used, yet M-skin
reveals that increasing values of this measure may be linked with a
‘progression’ from nevi to primary and metastasis melanoma
profiles.
We now introduce another useful technique to identify genes
which correlate with the transitions. The challenge is to find genes
which are related with the progression towards metastases profiles,
even when we recognize that there the group of metastasis samples
is heterogeneous (containing at least two groups). Since the final
outcome of Figure 4 and Figure 5 is that the Normalized Shannon
Entropy does not help much in this experimental scenario, we will
concentrate only on one of the multiplicative factors of the M-
complexities, the Jensen-Shannon divergence. We compute two Pave
profiles, one with the normal skin samples only, and the other with
all the metastasis samples (regardless their type). We will call the
two divergences JSM0 and JSM5 respectively. We then compute
the Spearman correlation of the profile of all gene probes in the
array across the 37 samples to both JSM0 and JSM5. We have
listed all probes according to the absolute value of the difference of
these correlations, i.e. Abs. Diff. (probe)=|JSM0(probe)2JSM5
Figure 4. Scatter plot of the samples of the melanoma dataset contributed by Haqq et al. It presents the MPR-Statistical Complexity of
each sample as a function of its Normalized Shannon Entropy. This dataset contains information of 14,737 probes and 37 samples. The samples
include 3 normal skin, 9 nevi, 6 primary melanoma and 19 melanoma metastases (these samples are 5 of melanoma metastasis ype I and 14 of type II,
as labelled by Haqq et al). Following Haqq et al’s original classification, the two types of melanoma metastases they identified are presented with
different color coding. The plot illustrates that in this case, the Normalized Shannon Entropy does not help to differentiate the normal to metastatic
progression (as it happened in the case of prostate cancer). We will show in Figure 5 that the modified statistical complexities M-skin and M-
metastasis allow visualizing a clearer transitional pattern.
doi:10.1371/journal.pone.0012262.g004
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PLoSONE-SupFile.xls, in the sheet labelled ‘Results-correlation’.
The rationale is to identify those probes which are highly
correlated (both positively or negatively) with the Jensen-Shannon
divergence of the normal tissue profile and that ‘‘reverse signs’’. For
instance, a probe for the TP63 gene (Tumor protein p63,
keratinocyte transcription factor KET), AA455929, is ranked in
the third position. Its correlation with the Jensen-Shannon divergence
of the normal skin type is relatively high and negative
(JSM0=20.63632) while at the same time is has a positive
correlation with the Jensen-Shannon divergence of the metastasis
profile (JSM5=0.62138). In the ranking, the first probe that
presents the opposite behaviour is one for ADA (Adenosine
deaminase), AA683578. Figure 6 helps to understand the
relationship of these correlations with expression. Not only are
these genes well correlated with the divergences, they also seem to
be good markers of the progression from one tissue type profile to
the metastasis profile.
We will now discuss three of these genes in the context of current
biological knowledge on melanoma drivers and metastatic progres-
sion. We provide many references for one of them, SPP1 (Secreted
phosphoprotein 1 or Osteopontin). The discussion on this gene will
be left for later, when we will discuss specifc oncosystems related to
cell proliferation, chemotaxis and responses to external simulus.
Figure 7 shows the expression of ADA (Adenosine deaminase,
AA683578) as a function of TP63 (keratinocyte transcription factor
KET, AA455929). All normal skin samples, as well as nevi and a
couple ofprimary melanomashaverelativelylowvaluesofADA but
they express TP63. There is a change of roles in metastatic and
some primary melanomas, which have reduced TP63 expression
butincreasedvaluesofexpression ofADA.Aswewill latersee, these
events correlate with other major transcriptional modifications
which involve dozens of genes and that we have been able to map
thanks to functional genomics bioinformatics tools. The role of
SPP1 will be discussed in that context after some references to
TP63, ADA, and PLK1 which follow.
TP63. The product of this gene [111,112] belongs to the same
protein family of its more famous relative, TP53, a gene that is
often mutated in human cancers [113] and highly regarded as a
key ‘‘tumor suppressor’’. TP63’s product, p63, is a homologous
protein to p53, which is considered to be phylogenetically newer
[114] and also regarded as an important apoptotic and cell-cycle
arrest protein. Mice that lack TP53 are born alive with a
propensity for developing tumours; mice that lack TP63 do not
appear to be tumour prone, although, new results are partially
contradicting earlier findings [115]. It appears that the diverse
roles of the isoforms of the p63 family reveal that there exists a
crosstalk with the different isoforms of the p53 family that needs to
be systematically investigated [116]. It has recently been shown
that p63 is a key regulator of the development of stratified
epithelial tissues [113] and that its deletion results in loss of
stratified epithelial and of all keratinocytes [117]. Melanocytes also
express two isoforms of p63 [118], but p63 expression is not
reported in 57 out of 59 tumors in a tissue microarray study
performed by Brinck et al. [119]. It is clear that the the role of loss
of expression of TP63 in melanoma warrants further investigation.
ADA - (Adenosine deaminase) and DPP4/CD26 (Dipeptidyl-
peptidase 4, CD26, adenosine deaminase complexing protein
2). A link between TP63 and ADA has already been reported in
the literature. ADA is a gene involved in cell division and
proliferatation [120] and it has been suggested to have a
regulatory role in dendritic cell innate immune responses
[121].Translational modification is also a function of p63. Sbisa et
al. have proved that ADA is a direct target of isoforms of p63, which
is an important discovery as ADA has two TP53 binding sites,
leading to a complex metabolic balance due to the different
relationships between this trio and p21 yet to be completely
elicitated [120,122]. Several studies indicate elevation of adenosine
deaminase levels in sera of breast [123], head and neck [124],
colorectal [125],acute lymphoblastic leukaemia[126]andlaryngeal
cancers [127].
We observe a marked increase of expression of a probe for ADA
withmelanomaprogression whileat the same time we observe a loss
of expression ofa probecorresponding toDPP4/CD26(Dipeptidyl-
peptidase 4, CD26, adenosine deaminase complexing protein 2), a
membrane-bound, proline-specific serine protease [128] that has
Figure 5. Scatter plot of the melanoma sample dataset of Haqq et al. This is the same set of samples of Figure 4 and we have used the same
color coding. We are now using the modified statistical complexity measures M-skin and M-metastasis II. As expected, normal skin samples (in green)
have a low value of the M-skin measure. Interestingly, most of the nevi samples (in yellow) have an intermediate value of the M-skin measure, and
most of the primary and metastatic samples have even larger values of M-skin. This result, together with our observation and analysis of Figure 4,
indicate that the Jensen-Shannon divergence of melanoma samples from the normal skin profile may be a relevant measure to quantitatively analyse
progression even when the whole gene expression dataset is used. We observe that, although the M-metastasis II measure has used all the samples
labelled as Type 2 (in Haqq et al.’s original contribution), their position in this plane shows two different clusters. This may indicate that a further
heterogeneity may exist in this subgroup, a fact that warrants further study with a larger group of samples.
doi:10.1371/journal.pone.0012262.g005
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previously reported that loss of DPP4 immunostaining helps to
discriminate malignant melanomas from deep penetrating nevi, a
variant of benign melanocytic nevus [130] and early reports of their
absence in metastatic melanomas exist [131,132]. As deep
penetrating nevi can mimic the vertical growth phase of nodular
malignant melanoma, and ADA could potentially be downregulat-
ing DPP4 [133,134] we believe that the elicitation of the
complementary role of these two biomarkers to distinguish these
two entities is necessary and also warrants further clinical studies.
PLK1 (Polo-like kinase 1 (Drosophila)). Another probe for
gene that ranks high as a positive marker of metastasis is PLK1,
Polo-like kinase 1, Serine/Threonine protein kinase 13
(AA629262). PLK1 is a centrosomal kinase [135] which is
Figure 7. Scatter plot showing the expression of the probe corresponding to ADA (Adenosine deaminase), AA683578 (y-axis) and
TP63 (Tumor protein p63), AA455929 (x-axis). All the samples that have TP63 expression are normal or nevi, with two primary melanomas still
preserving TP63 expression but with higher ADA. The trend reverses for the rest of the primary melanoma samples and the metastatic ones, which all
express ADA but not TP63.
doi:10.1371/journal.pone.0012262.g007
Figure6.AscatterplotoftheSpearmancorrelationof14,737probesintheHaqqetal.melanomadataset.WehavecomputedtheJensen-
Shannon divergence of each sample with the normal skin average. We then computed the correlation of each individual probe expression with the
Jensen-Shannon divergence of each sample. As this correlation is computed on all samples, the resulting value (x-axis) was denoted as JSM0A-Spearman.
Analogously, we compute the Jensen-Shannon divergence of each sample with the average metastastic profile and we also compute the correlation of
each probe with this measure (y-axis). The position of one probe corresponding to the TP63 gene (Tumor protein p63, keratinocyte transcription factor
KET), AA455929, is highlighted. The expression of this probe has a relatively high negative correlation with the Jensen-Shannon divergence of the normal
skin type (JSM0-Spearman=20.63632) while at the same time is has a positive correlation with the Jensen-Shannon divergence of the metastasis profile
(JSM5=0.62138). The first probe that presents an opposite behaviour is one for ADA (Adenosine deaminase), AA683578. Probes for SPP1 (Secreted
phosphoprotein 1 or Osteopontin) and PLK1 (Polo-like kinase 1 or Drosophila) are also highlighted. While PLK1 is currently less recognized as a
biomarker in melanoma research, the importance of SPP1 in cutaneous pathology [315,318,320,321] and in particular in melanoma
[208,209,210,211,212,214,215,216,217,218,219,222,226,264,314,315,316,317,319,322,323,324,325,326,327,328,804,805,806,807,808,809] is increasing. Us-
ing a 5-biomarker panel that included SPP1, Kashani-Sabet et al. used tissue microarrays on 693 melanocytic neoplasms to show that SPP1 expression
collaborates significantly improving the detection of high percentage of melanomas arising in a nevus, Spitz nevi, dysplastic nevi and misdiagnosed
lesions [253]. Like in the case of prostate cancer (Figure 3, in which KLK3/PSA - Prostate Specific Antigen was highlighted), our method allows the
detection of important biomarkers with a high degree of concordance with current biological understanding of metastatic processes.
doi:10.1371/journal.pone.0012262.g006
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assembly [135]. PLK1 expression has also been singled out as a
biomarker of a ‘‘death-from-cancer’’ signature, sharing with others
the function of being an activator of mitotic spindle check point
proteins. With other proteins it would has a stem cell-like
expression profile phenotypically characterized by enabling
metastasis with anoikis resistance and disregulated cell-cycle
control [136]. PLK1 inhibition could be a common target for
gastric adenocarcinoma [137], bladder cancer [138], colon cancer
[139,140], hepatocellular carcinoma [141], medullary thyroid
carcinoma [142], esophageal cancer [143], pancreatic cancer
[144] and in some types of non-Hodgkin lymphomas [145] and
breast cancer [146].
PLK1’s Spearman correlation with the values of the Jensen-
Shannon divergence of samples with the normal skin profile is
relatively high (0.5863). PLK1 also has a high value of (negative)
Spearman correlation with the values of the Jensen-Shannon
divergence of samples with the average metastatic profile
(20.44571). In 2002 Kneisel et al. have conducted a study to
investigate the expression of PLK1 in very thin melanomas
(smaller or equal to 0.75 mm). On 36 patients, within five-years of
follow-up, 22 melanomas developed metastases while 14 did not.
In the comparison, it was found that metastatic malignant
melanomas with expressed PLK1 at markedly elevated levels
(median, 60.00% vs. 37.98%; p-value,0.000053), concluding that
PLK1 is a reliable biomarker for patients at high risk of metastases,
even when the most important prognostic clinical factor (Breslow’s
maximum thickness of the primary malignant melanoma) indicates
the contrary [147]. We consider this an important finding as
PLK1 silencing is already part of an integrated oncolytic
adenovirus approach currently being studied in mice models of
orthotopic gastric carcinoma [148] and has promise due to the
lack of a reported measurable immune response of siRNA-based
therapeutics [149]. Another positive note is the less sensitivity to
PLK1 depletion of cells with a functional p53 [150,151], and can
help to sensitize cells to chemotherapy (as observed in lung cancer
[152]). This constraint of aneuploid cancer cells to PLK1
expression, particularly in cells with inactivated p53 [153], could
be exploited by lentivirus-based RNA interference [154].
Correlation analysis with Jensen-Shannon divergences reveals biomarkers for
loss of cell adhesion, cell-cell communication, impairment of tight junction
mechanisms and dysregulation of epithelial cell polarity.
As discussed before, the probe for ADA (Adenosine deaminase)
is the first that has a different trend. Since we put all metastasis
samples together in the same group when we calculated the
average probability profile (and we have a heterogeneous group)
we have on our ranking 58 probes that appear before ADA (we
refer to the Supplementary File Haqq-PLoSONE-SupFile.xls). An
analysis using GATHER (http://gather.genome.duke.edu/) [155]
to interpret the collective influence of the lack of expression of all
these genes in the metastasis samples reveals an interesting new
perspective. Using Gene Ontology, we found that six of the 44
genes identified by GATHER are related to epidermis develop-
ment (CDSN, DSP, EVPL, GJB5, KRT13, KRT5), p-value
,0.0001, Bayes Factor 16, and eight genes are related to cell
adhesion (CDSN, CLDN1, DSG1, DST, LGALS7, LRIG3,
PCDH21, PKP1), p-value,0.0001, Bayes Factor 7. ANK1 (Ankyrin
1, erythrocytic), AA464755 was also singled out as by our Gene
Ontology analysis as related to the maintenance of epithelial cell
polarity (p-value=0.002, Bayes Factor 3). The use of another profiler
of genome signatures (g:Profiler, [156]) also reinforces the view
that many genes that have lost expression are related to ‘Epidermis
Development’ (COL17A1, DSP, EVPL, GJB5, KRT13, KRT5,
LCE1C, MAFG, TGM3) with p-value=7.78E-11. Thirteen are
associated with Gene Ontology function of cell communication
(ANK1, CDSN, CLDN1, DSG1, DST, GCHFR, GJB5, GPR115,
LGALS7, LRIG3, PCDH21, PKP1, PTGER3), albeit with a p-
value of only 0.02. GCHFR is also involved in nitric oxide
metabolism.
If we add to the list of 44 genes already recognized by
GATHER the other 77 probes that after ADA in this ranking have
also loss of expression (until we found PDXP (Pyridoxal
(pyridoxine, vitamin B6) phosphatase), the evidence is stronger,
now COL7A1, GJB5, KLK4, and KRT1 also is in this group (the
Bayes factor of this association returned by Gather is now 21 for
the GO term ‘Epidermis development’). ‘Cell adhesion’ has now 13
genes, CDSN, CLDN1, COL7A1, DSC2, DSG1, DST, JUP,
LGALS7, LRIG3, PCDH21, PKP1, SLIT3 THBS3 (p-val-
ue,0.001, Bayes factor 10). These results are considered
statistically very relevant as identifiers of a particular process
which seems to be undermined by this collective loss of expression.
If we put all this information together, we clearly observe a
pattern of downregulation of gene expression that is associated
with an impairment of epidermis development and the main-
tainance of its structure (Figure 8 and Table 1). This is, perhaps,
an instantiation of one of the ‘‘extended hallmarks of cancer’’ (that
of ‘‘tissue dedifferentiation’’). This process includes the loss of function
of genes that are essential for the maitainance of tight junction and
epithelial cell-cell communication. While loss of epithelial structure
is related to these genes, we observe that those that increase
expression are associated to other developmental processes, not
necessarily concerted in this panel. Instead they show a pattern of
increasing cell motility, chemotaxis and positive regulation of cell
proliferation. We will first discuss the processes related to the loss
of adhesion, which could be linked to an increased probability of
metastatic potential of these cells.
The loss of expression of Plakophilin 1, Junction plakoglobin, Desmoplakin
and Desmoglein 1 indicate deficiencies in desmosome processes.
In general, this panel is composed of a number of genes that are
losing expression during progression and that have Gene Ontology
annotations related to tight junctions, gap junctions, adherens
junctions and desmosomes, and an impaired set of processes that
link, via intercellular channels and bridges, the cells of the
epidermis. Mutations in these genes are linked to a number of skin
genetic diseases [157,158,159,160,161,162,163,164,165,166,167,
168,169,170]
The desmosome are cell-cell adhesive junctions which provide a
mechanical coupling between cells. These junctions are found in
several epithelial tissues and the decreased assembly of the
desmosome has been shown to be a common feature of many
epithelial cancers [171,172]. Plakoglobin helps to connect
transmembrane elements to the cytoskeleton [173]. Plakophilin 1
[174] (PKP1, one of the genes in our panel above) is a desmosomal
plaque component [175] that stabilizes desmosomal proteins at the
plasma membrane [176,177] and, with desmoplakin [178],
recruits filaments to sites of cell-cell contacts [179]. As a
consequence, it has been proposed that the lack of PKP1 increases
keratinocyte migration [180] and loss of PKP1 expression in head
and neck squamous cell carcinoma and in esophageal squamous
cell carcinoma may contribute to an invasive phenotypic
behaviour [171], perhaps as a consequence of the impaired
recruitment of desmoplakin.
The desmoglein-specific cytoplasmic region (DSCR) is the site
of caspase cleavage during apopotosis and is a conserved region of
yet undefined function and unknown structure, but it specifies the
function of the desmoglein family of cell adhesion molecules (of
which DSG 1 is a member). It has been recently shown that the
DSCR has a weak interaction with PKP1, Plakophilin 1
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domain of Desmocollin 1 [181]. Plakoglobin is cleaved by Caspase
3 during apoptosis [182]. In addition, Kami et al. in Ref [181] also
report and conclude that: ‘‘desmoglein 1 membrane proximal region also
interacts with all four DSCR ligands, strongly with plakoglobin and
plakophilin and more weakly with desmoplakin and desmocollin 1. Thus, the
DSCR is an intrinsically disordered functional domain with an inducible
structure that, along with the membrane proximal region, forms a flexible
scaffold for cytoplasmic assembly at the desmosome’’.
As previously discussed, all these genes progress towards a loss of
expression, and they are highly correlated. Figure 9 shows the
average expression of PKP1/Plakophilin 1 (ectodermal dysplasia/
skin fragility syndrome), (NM_000299) and JUP, Junction
plakoglobin, (BX648177) on the x-axis against that of DSP,
Desmoplakin (NM_004415 Hs.519873) on the y-axis. Again, we
see a clear pattern of progressive reduction of expression from
normal skin and nevi (green and yellow, respectively), primary
melanomas (in orange) and melanoma metastases (red).
Joint loss of expression of Claudin 1 and members of the Aquaporin family
are also linked to a transition to a more malignant phenotype
We note however, the Gene Ontology annotation is not the only
way that we can make sense of this information. A detailed analysis
of that list of 58 genes reveals other proteins involved in tight
junction, like Aquaporin 3 (AQP3). Probes for AQP3 and Claudin
1 (CLDN1) have reduced expression with the progression of the
disease as shown in Figure 10.
AQP3 (Gill blood group) is a member of the aquaporin
family of proteins, and currently is recognized as an ‘aquaglycer-
oporin’ [183] of great importance to maintain skin hydration of
mammals epidermis [184]. Three proteins of this family (AQP1,
AQP3, and AQP9) have probes that seem correlated with
melanoma progression, all losing their expression in the process
of going from normal skin to metastatic melanoma. AQP3 water
channels have been pointed out as an essential pathway for
volume-regulatory water transport in human epithelial cells [185].
AQP3 is also selective for the passage of glycerol and urea and it
has been suggested that osmotic stress up-regulates AQP3 gene
expression in cultured keratinocytes [186]. AQP3 was found to be
the predominant aquaporin in human skin which increased
expression and altered cellular distribution of AQP3 in eczema
thus contributing to water loss [187]. The putative involvement of
aquaporins in the progression of melanoma, uncovered by our
method in our results, warrants further investigation as it has been
recently shown that another member of this family (AQP8) also
facilitates hydrogen peroxide diffusion across membranes [188]. It
is suspected that AQP3 has other functions with a suggestion that
it is involved in ultraviolet radiation induced skin dehydration
[189]. There is no probe for AQP8 in Haqq et al.’s dataset that we
could scrutinize from its trend with progression but we note that a
novel strategy for drug development for melanoma (i.e. Ele-
sclomol) works by inducing apoptosis via a mechanism of elevation
of reactive oxygen species (of course, including hydrogen peroxide
in cancer cells) thus exploiting the ‘‘Achilles hell of cancer metabolism’’
[190].
Claudin 1, CLDN1 [191], a gene which is reported to be
‘‘normally expressed in all the living layers of the epidermis’’ [192], in
concert with AQP3, is a key component of the tight junction
complexes of the epidermis. Low CLDN1 gene expression was
correlated with shorter overall survival in lung adenocarcinoma.
Overexpression of CLDN1 was correlated with suppression of
cancer cell migration, invasion and metastasis [193]. Hoevel et al.
report that re-expression of CLDN1, in breast tumor spheroids,
induces apoptosis and they conclude: ‘‘These findings support a
potential role of the tight junction protein CLDN1 in restricting nutrient and
growth factor supplies in breast cancer cells, and they indicate that the loss of
the cell membrane localization of the tight junction protein CLDN1 in
carcinomas may be a crucial step during tumor progression’’ [194]. Tokes et
al.also report that malignant invasive breast tumors are negative
Figure 8. Heat map of the expression of 27 probes with genes annotated showing functions on cell adhesion, cell-cell communication,
tight junction mechanisms and epithelial cell polarity. The average expression of the skin samples is shown in green. In yellow, the nevi samples,
showing that some of them have a reduced average expression. The primary melanomas have a mixed behaviour (orange columns) with four of them
having almost zero of negative average expression. The metastatic samples (columns in red) have all a negative average expression. Overall the figure
indicates a progression, from the positive average expression of this gene panel for nevi and normal skin samples, towards negative expression
values of the metastatic samples, ‘‘passing’’ through the mixed behaviour present in primary melanomas.
doi:10.1371/journal.pone.0012262.g008
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PLoS ONE | www.plosone.org 11 August 2010 | Volume 5 | Issue 8 | e12262Figure 9. Shows the average expression of PKP1 and JUP. The joint expression of the probe for PKP1 (Plakophilin 1 - ectodermal dysplasia/
skin fragility syndrome - NM_000299) and the probe for JUP (Junction plakoglobin - BX648177), as added values on the x-axis, against the expression
of the probe for DSP (Desmoplakin - NM_004415 Hs.519873) on the y-axis. There is a clear common downregulation trend of these biomarkers from
the normal skin (Skin) to the nevi (MN) and to the primay melanoma and metastic melanoma samples (PM and MM respectively).
doi:10.1371/journal.pone.0012262.g009
Table 1. Gene names and probe accession number of the 27 probes with genes annotated with functions on cell adhesion, cell-cell
communication, tight junction mechanisms and epithelial cell polarity shown in the heat map in Figure 8.
THBS3 NM_007112 Hs.169875 Thrombospondin 3
TGM3 AK290324 Hs.2022 Transglutaminase 3 (E polypeptide, protein-glutamine-gamma-
glutamyltransferase)
SLIT3 BC098388 Hs.604116 Slit homolog 3 (Drosophila)
PTGER3 NM_198715 Hs.445000 Prostaglandin E receptor 3 (subtype EP3)
PKP1 NM_000299 Hs.497350 Plakophilin 1 (ectodermal dysplasia/skin fragility syndrome)
PCDH21 NM_033100 Hs.137556 Protocadherin 21
MAFG NM_002359 Hs.252229 V-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian)
LRIG3 AY358288 Hs.253736 Leucine-rich repeats and immunoglobulin-like domains 3
KRT 5M21389 Hs.433845 Keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-
Cockayne types)
LGALS7 BM913998 Hs.558355 Lectin, galactoside-binding, soluble, (galectin 7)
LCE1C NM_178351 Hs.516429 Late cornified envelope 1C
KRT13 CR591347 Hs.654550 Keratin 13
JUP BX648177 Hs.514174 Junction plakoglobin
GPR115 NM_153838 Hs.710050 G protein-coupled receptor 115
GJB5 AK129509 Hs.198249 Gap junction protein, beta 5, 31.1kDa
GCHFR BQ054887 Hs.631717 GTP cyclohydrolase I feedback regulator
EVPL NM_001988 Hs.500635 Envoplakin
DST NM_183380 Hs.631992 Dystonin
DSP NM_004415 Hs.519873 Desmoplakin
DSG1 NM_001942 Hs.2633 Desmoglein 1
DSC2 BC063291 Hs.95612 Desmocollin 2
COL17A1 NM_000494 Hs.117938 Collagen, type XVII, alpha 1
CLDN1 NM_021101 Hs.439060 Claudin 1
CDSN NM_001264 Hs.556031 Corneodesmosin
ANK1 NM_000037 Hs.654438 Ankyrin 1, erythrocytic
doi:10.1371/journal.pone.0012262.t001
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expression correlated with recurrence status, the low expression of
CLDN1 and other tight junction proteins seems to contribute to
cellular detachment.
The complementary set of correlations with the Jensen-Shannon divergences
unveils biomarkers for cell proliferation, chemotaxis, and responses to external
simulus.
If the use of Gene Ontology has produced very peculiar results,
helping us to link the loss of expression of 44 genes with a
significant change in epithelial structure and development. A
natural question arises: ‘‘Which is the significance of another set, now
arbitrarily chosen to be also of the same cardinality (i.e 44 genes) with the
complementary behavioural pattern?’’ We have now listed all the probes
according to Diff. (probe)=JSM0(probe)2JSM5(probe) in decreasing
order. The results are provided as Haqq-PLoSONE-SupFile.xls
(‘Results-correlation’ sheet). This now gives ADA as the first
ranked gene. Again using GATHER [155] on the first 44 genes
recognized by the software, and again using Gene Ontology, we
observe as most important common function that of cell motility
(CCL3, CXCL10, FPRL1, SEMA6A, SPP1), p-value=0.0002,
Bayes Factor 5, and chemotaxis (CCL3, CKLFSF7, CXCL10,
FPRL1, SPP1), p-value,0.0001, Bayes Factor 7. The genes
CXCL10, SPP1, and WARS, together with another gene that
has been annotated as related to positive regulation of mitosis (SCH1),
have also been annotated as regulators of cell proliferation (p-
value=0.007, Bayes Factor 2). Using the g:Profiler software [156],
we obtain a complementary information. Sixteen genes (including
SPP1, SEMA6A, LEF1 [197], CD230, ALS2CR2, DKK1,
CYFIP2, SHC1, ANKRD7, IFI6, CITED1, and MID1) have
been associated to the Gene Ontology term of ‘developmental process’.
SPP1 - Secreted phosphoprotein 1 (osteopontin). SPP1 is
one of the most conspicuous melanoma biomarkers
[198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,
213,214,215,216,217,218,219,220,221,222] (see also the refer-
ences cited in Figure 6 and note its eminent position in this scatter
plot). In 1990, Craig et al. reported that SPP1 may work as an
autocrine adhesion factor for tumor cells (see also [204,223,224]).
They observed that ‘‘SPP1 mRNA, which is barely detectable in normal
mouse epidermis, was expressed at moderate-to-high levels in 2 of 3 epidermal
papillomas and at consistently high levels in 7 of 7 squamous-cell carcinomas
induced by an initiation-promotion regimen’’ [225]. The evidence is being
constantly expanded on the role of SPP1 as a molecular prognostic
biomarker in melanoma [226]. Activation of SPP1 may be an
important event that allows the transformed melanocytes to invade
the dermis as proposed by Geissinger et al. in 2002 [208]. This
causes SPP1 to avoid the apoptotic stimulus, one of the ‘‘hallmarks
of cancer’’, which invasive cells will be receiving from this new
tissue.
If we extend the literature-based search so that we now include
the first 200 gene probes recognized by GATHER then we have
27 gene probes associated with the Gene Ontology in terms of ‘‘cell
proliferation’’ (p-value=0.0002, Bayes Factor 5), and ‘regulation of cell
proliferation’, p-value=0.003, Bayes factor 3). However, other partners
of PLK1 appear and their function in ‘mitotic cell cycle’( p-
value=0.0003, Bayes Factor 5) is increasingly present (in particular,
the M phase of the mitotic cell cycle). The details of the Gene
Ontology terms which are significant and the genes associated to
them are listed in Table 2.
The analysis using g:Profiler largely coincides with the analysis
using GATHER, however, it retrieves 12 genes associated with the
M phase of mitotic cell cycle, namely: AURKA and AURKB
[227,228,229], BUB1 [230,231], CDCA5A/Sororin/p35 [232],
CDC7 [233,234], CHEK1 [235], KIF23/MKLP-1 [227,236,237],
MAP9/ASAP [238,239], NCAPD3, NCAPG2 [240], NEK6
[241,242,243,244], PLK1 [147,245,246], PTTG1/Securin [247],
SHC1/p66 [248,249,250] (discussed in the context of SHC4
signalling), and TFDP1/DP-1 [251]. These are a significant finding
by g:Profiler (p-value=4.03E-07).
We have listed above some of the genes gene associated to the
M phase of mitotic cell cycle and associated references which are
either to current research in melanoma and/or its biological
function. We now list other genes which have been associated with
the term ‘cell proliferation’ by GATHER. These genes are:
ARPC1B [252], ARPC2 (which, together with SPP1, is also in the
novel 5-biomarker panel of Kashani-Sabet et al. [253]), BCCIP
(BRCA2 and CDKN1A-interacting protein)/P21-and CDK-
Figure 10. Expression of a probe for CLDN1 (Claudin 1) (y-axis) as a function of a probe for Aquaporin 3 (x-axis). Other members of the
aquaporin family of proteins have a similar behaviour. AQP3, together with CLDN1 are key components of the tight junction complexes of the
epidermis and their joint loss of expression seem to be related to a transition to a more malignant phenotype. We use the same color coding as
Figure 9.
doi:10.1371/journal.pone.0012262.g010
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2/Tetherin [255], CCL3/MIP-1alpha [256,257,258], CCT4,
CDCA5/Sororin [259,260,261,262,263], CENPF/Mitosin [264],
CXCL1/chemokine (C-X-C motif) ligand 1 (melanoma growth
stimulating activity, alpha) [265,266,267,268,269,270,271,272,
273,274,275,276,277,278,279,280,281,282,283,284,285] (in uveal
melanoma see [286]), CXCL10 [256], FLT1/VEGFR1 [287,
288,289,290,291,292,293,294,295,296,297,298,299], FTH1/Fer-
ritin Heavy Chain [300,301,302] (which may indicate a necessary
condition for the mainainance of iron sequestration and
suppression of reactive oxygen species accumulation [303]),
FPRL1, LIG3/DNA Ligase 3 [304] (which, together with XPA
and ERCC5 is associated to DNA repair in ionizing radition
studies [305]), MCMDC1, PSEN2, NRP2/Neuropilin 2/Vascular
endothelial cell growth factor 165 receptor 2 [306,307,308],
SEMA6A (a member of the Semaphorin family, of increasing
importance in cancer research [309,310,311] and in particular due
to its observed upregulation in undifferentiated embryonic stem
cells [312]), SLAMF1/CD150 (a marker associated with hemato-
poietic stem cells [313]), SPP1/Osteopontin (which, together with
ARPC2, is also in the novel 5-biomarker panel of Kashani-Sabet
et al. [253]) [206,207,208,209,210,211,212][206,207,208,209,210,
211,212,214,215,216,217,218,219,220,221,222,226,314,315,316,-
317,318,319,320,321,322,323,324,325,326,327,328,329], STK6
[230,330], and WARS/Tryptophanyl-tRNA synthetise [331].
Figure 11 shows a heat map of discussed gene probes annotated
with functions on cell proliferation.
The references provided next to each gene help to related these
upregulated genes in the context of current research in melanoma
or with the M phase of mitotic cell cycle, showing a high degree of
correlation between our results and with published literature.
Prostate Cancer - True et al.’s dataset (File S3)
Another microarray dataset we have selected to evaluate for the
relevance of transitions of Normalized Shannon Entropy and Statistical
Complexity was contributed by True et al. [332] in 2006.
The original goal of True et al. was to identify a molecular
correlate for Gleason patterns 3 and, if possible, the clinically most
worrisome patterns 4 and 5. They partially succeeded by linking
the expression of only 86 genes with Gleason pattern 3 [332] using
a standard statistical analysis. In this study, we eliminated sample
02-209C since data was acquired using a different platform and
would not be useful for our analysis. The remaining thirty one (31)
samples were assayed with the GPL3834 (FHCRC Human
Prostate PEDB cDNA Array v4) platform using 15,488 probes.
We also eliminated all the probes with missing values, remaining
13,188 probes.
We have first plotted the samples on the (Normalized Shannon
Entropy, MPR-Statistical Complexity) plane (Figure 12). It was
interesting to observe that there exists a high correlation between
the two measures. Samples that are entirely composed of Gleason
pattern 3 tend to have a greater value of Normalized Shannon Entropy
than 0.985. We can also identify a cluster of samples that present
Gleason patterns which are either 4 or 5. Note that there seems to
be two outliers (02_003E and 03_063) to the generic trend of the
other 29 samples. The two outliers are samples that correspond to
samples labelled as having Gleason 3 patterns and both have
unusually low values of Normalized Shannon Entropy that are well
below the values of the rest of the group.
This raised a suspicion about the true nature of this
phenomenon. If the labelling is correct, this may indicate a
subsampled group of prostate cancer that has Gleason 3 pattern
characteristics but very low entropy. Alternatively, it may indicate
an experimental bias for reasons we can not explain with the
available clinical information. In order to clarify the situation, and
see if we can declare these two samples as outliers of the other
group, we performed another experiment. We have now com-
puted two modified complexities, which we will call M-Gleason 3
and M-Gleason 5 (Figure 13). The names are probably self-
explanatory, but a brief reminder follows. To calculate the MPR-
Complexity, by definition, we have used the equiprobable
distribution as our probability distribution of reference (for the
computation of the Jensen-Shannon Divergence of the gene expression
profile to this distribution). In the case of the M-Gleason 3, the
probability distribution of the reference is obtained averaging all
the probability distributions of the samples that have been labelled
as Gleason 3 (analogously, we calculated M-Gleason 5). Samples
that have Gleason pattern 3 and 5 appear as separate clusters in
the (M-Gleason 3, M-Gleason 5) plane with the two putative outliers
of the general trend far apart (even if they have been used to
calculate the average probability distribution function of the
Gleason 3 pattern). Even samples with Gleason 4 pattern are
located closer to samples of Gleason patterns 3, and 5, indicating
that, perhaps, there exists a subsampled subtype of prostate cancer
or there might be another experimental bias or factor that at
present we can not resolve with the information we have for these
samples. Consequently, we have decided to eliminate both samples
(02-003E and PNA_03-063A) from further calculations. With
these considerations, we now have a dataset with 13,188 probes
and 29 samples as our dataset for further analysis.
Table 2. Significant Gene Ontology terms and their associated genes.
Gene Ontology annotation Genes p-value
Bayes
factor
GO:0008283 [4]: cell proliferation 27 (AURKB BCCIP BST2 BUB1 CCT4 CDC7 CDCA5 CENPF CHEK1 CXCL1 CXCL10 DNAJC6 FLT1
FTH1 IFI16 KIF23 LIG3 MCMDC1 PLK1 PSEN2 PTTG1 SHC1 SLAMF1 SPP1 STK6 TFDP1 WARS)
0.0002 5
GO:0000278 [6]: mitotic cell cycle 10 (BCCIP BUB1 CDC7 CENPF CHEK1 KIF23 PLK1 PTTG1 SHC1 STK6) 0.0002 5
GO:0000280 [7]: nuclear division 9 (BUB1 CENPF CHEK1 KIF23 LIG3 PLK1 PTTG1 SHC1 STK6) 0. 0003 4
GO:0000279 [6]: M phase 9 (BUB1 CENPF CHEK1 KIF23 LIG3 PLK1 PTTG1 SHC1 STK6) 0.0004 4
GO:0007067 [8]: mitosis 7 m(BUB1 CENPF KIF23 PLK1 PTTG1 SHC1 STK6) 0.003 3
GO:0042127 [5]: regulation of cell proliferation 10 (CDC7 CHEK1 CXCL1 CXCL10 FLT1 FTH1 SHC1 SLAMF1 SPP1 WARS) 0.003 3
GO:0000087 [7]: M phase of mitotic cell cycle 7 (BUB1 CENPF KIF23 PLK1 PTTG1 SHC1 STK6) 0.003 3
GO:0006928 [4]: cell motility 8 (ARPC1B ARPC2 CCL3 CXCL10 FPRL1 NRP2 SEMA6A SPP1) 0.004 2
doi:10.1371/journal.pone.0012262.t002
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Normalized Shannon Entropy and the MPR-complexity. By definition,
the positions of the 29 samples in the plane do not change (this
figure is basically ‘‘zooming in’’ one region of Figure 12 that
contains these samples). We note again, however, that the 29
samples seem to be separating in three different clusters. Whether
we can argue about the existence or not of these gaps in Normalized
Shannon Entropy, it is clear that there seems to be a progression as
we have seen with Lapointe et al’s dataset. There is a group of
three samples with Gleason pattern 3 that seem to have the the
largest Normalized Shannon Entropy values. There is also a cluster that
only contains samples of either Gleason pattern 4 and 5, all with
Normalized Shannon Entropy values smaller than 0.985.
There is also very little variation (see Figure 15) of the positions
of the 29 samples on the (M-Gleason 3, M-Gleason 5)-plane,
indicating a degree of robustness that the computation of these
modified complexities have, even in the presence of some outliers.
Correlations of the genes’ expressions profiles across
samples with the transitions of Entropy
After observing that Figure 14 shows a correlation of Gleason
pattern score with Normalized Shannon Entropy, we asked ourselves:
‘which are the genes that most positively and negatively correlate with the
transitions of Normalized Shannon Entropy?’ We have plotted Spearman
versus Pearson correlation values of probe expressions to attempt to
find those that best correlate, either positively or negatively,withthe
Normalized Shannon Entropy values of the samples. The results have
revealed some of the most relevant biomarkers of progression, and
some unexpected newcomers. Figure 16 shows the Pearson and
Spearman correlations of all the 13,188 probes in the dataset with
the Normalized Shannon Entropy values of the samples. We have
highlighted some particular genes that are discussed below.
CDKN2C (cyclin-dependent kinase inhibitor 2C (p18,
inhibits CDK4). When we compute the correlations of the
probes expressions with the Normalized Shannon Entropy values of the
samples, the gene that has the most negative correlations is
CDKN2C (cyclin-dependent kinase inhibitor 2C - p18, inhibits
CDK4 - NM_078626), which has been previously associated with
the transition from prostatic intraepithelial neoplasia (PIN) to
prostate cancer [68] (Spearman correlations with the Normalized
Shannon Entropy range between 20.8010 and 20.7276 for all the
probes for NM_078626 in this array). It has been recently argued
that CDKN2C and PTEN partner in tumor suppression by
constraining a positive regulatory loop between cell growth and
cell cycle control pathways. Bai et al. reported that a ‘‘double mutant
mice develop a wider spectrum of tumors, including prostate cancer in the
anterior and dorsolateral lobes, with nearly complete penetrance and at an
accelerated rate’’ [333]. Using the cancer cell lines LNCaP, PC3,
PC3M, PC3M-Pro4, and PC3M-LN4 and three immortalized
prostate epithelial cell lines Wang et al. report hypermethylation of
CDKN2C [334].
Figure 11. Heat map of the expression of 38 gene probes annotated with functions on cell proliferation, in particular cell motility,
mitotic cell cycle, nuclear division, and specifically, M phase of mitotic cell cycle. We have used the same convention we employed in Figure 8: in
green, the normal skin samples; in yellow, the nevi samples; the primary melanoma samples (in orange) show increased expression for most of these
biomarkers. This may indicate that the upregulation of genes involved in these processes is an earlier event (it occurs as a common feature in all the
primary melanoma samples) while modifications to cell adhesion, cell-cell communication, tight junction mechanisms and epithelial cell polarity occur
later (primary melanomas in Figure 4 show a transition). Finally, the metastatic samples (in red) show some heterogeneity, but overall provide an
increased expression. The average expression of this panel could be a good indicator of the transition from nevi to a malignant phenotype, while the
panel of Figure 8 can complement the information indicatingthe onset of tissue dedifferentiation processes.
doi:10.1371/journal.pone.0012262.g011
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(Monoamine oxidase type A), two for NM_000240 and two for
BC008064, follow closely with CDKN2C (Spearman correlations
with Normalized Shannon Entropy ranging between 20.7650 and
20.7202 echoing the interest of True et al. and other researchers
on MAOA [332,335,336,337]). Zhao et al. have recently reported
that ‘‘MAO-A is also expressed in the basal epithelial cells of normal prostate
glands. Using cultured primary prostatic epithelial cells as a model, we showed
that MAO-A prevents basal epithelial cells from differentiating into secretory
cells. Under differentiation-promoting conditions, clorgyline, an irreversible
MAO-A inhibitor, induced secretory cell-like morphology and repressed
expression of cytokeratin 14, a basal cell marker’’. They also observed
mRNA and protein expression of AR, the androgen receptor
[338]. Peehl et al. now report correlation of MAOA expression
Figure 13. Scatter plot of the samples in the prostate cancer dataset contributed by True et al. We have used the same color coding
convention we have used in Figure 12. We plot the values of two modified statistical complexities, which we will call M-Gleason 3 and M-Gleason 5.
Instead of using the equiprobable distribution as our probability distribution of reference (for the computation of the Jensen-Shannon Divergence of
the gene expression profile to this distribution), as required for the MPR-Statistical Complexity calculation, we used a different one. For the M-Gleason
3, the probability distribution of the reference is obtained averaging all the probability distributions of the samples that have been labelled as
Gleason 3 (analogously, we calculated M-Gleason 5). This is analogous to our approach in melanoma (Figure 5) in which we used normal and
metastatic samples as reference sets for a modified statistical complexity. We observe that, even in this case, 02_003E and 03_063 continue to appear
as outliers. In addition to the evidence, we have observed that the deletion of these two samples did not significantly alter the identification of
biomarkers.
doi:10.1371/journal.pone.0012262.g013
Figure 12. Scatter plot of the samples in the prostate cancer dataset contributed by True et al., presenting the MPR-Statistical
Complexity of each sample as a function of its Normalized Shannon Entropy. The dataset contains the expression of 13,188 probes and 31
samples. The samples include 11 samples labelled ‘Gleason 3’ (in green), 12 ‘Gleason 4’ samples, and 8 ‘Gleason 5’ (in red). Two samples seem to be
outliers to a generic trend, which is somewhat expected. We do expect samples with a ‘Gleason 3’ label to have higher values of Normalized Shannon
Entropy. This is indeed the case, no sample with a ‘Gleason 3’ label has a value of Normalized Shannon Entropy lower than 0.985, while 14 samples
corresponding to samples which are either ‘Gleason 4’ or ‘Gleason 5’ have values smaller than that threshold. In agreement with some of the caveats
discussed by True et al., there exist a group of samples that, irrespective of their label, have similar values of Normalized Shannon Entropy (near 0.992).
Samples 02_003E and 03_063 seem to be outliers to this trend, and in the case of 03_063 the sample is not even close to a hypothetical linear fit
which seems to be the norm for all the samples. Figure 13 will provide further evidence that may indicate that these two samples are outliers or not
to the overall trend.
doi:10.1371/journal.pone.0012262.g012
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and the percent of Gleason 4 and 5 cancers [338].
AMACR, Cyclin G2, CDK4 and CDK7. Other probes that
also have high negative correlations with the Shannon Normalized
Entropy correspond to CCNG2 (Cyclin G2) CR598707, CDK4
(Cyclin-dependent kinase 4), CDK7 (Cyclin-dependent kinase 7,
TFIIH basal transcription factor complex kinase subunit) [339],
and AMACR (Alpha-methylacyl-CoA racemase), an ‘‘obscure
metabolic enzyme (that has taken) centre stage’’ [340] as judged by the
extraordinary convergence to this biomarker in prostate. We
believe that our result is an important finding. AMACR was not
judged of importance according to the methodology used in [332]
and it was barely cited in that manuscript. Here we present results,
from an unifying biological and informational principle, which
allows (using Ref. [332]’s own data) the identification of the most
central current biomarker with a truly compelling body of support
in independent studies [316,340,341,342,343,344,345,346,347,
348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,
363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,
378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,
393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,
408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,
423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,
438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,
453,454] that currently exists in prostate cancer.
TP53 and BRCA1. There exist several studies linking two
‘‘tumor suppressors’’ BRCA1 and TP53, its expression, status and
mutations, to prostate cancer progression [51,55,455,456,457,458,
459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,
474,475,476,477,478,479,480,481,482,483,484,485]. BRCA1 is
one coregulator of AR, the androgen receptor [486,487,488,
489] and inhibits ESR1 (Estrogen receptor alpha) activity
[490,491]. Knockdown of BRCA1 results in the accumulation
of multinucleated cells, indicating that BRCA1 regulates gene
expression of an orderly progression during mitosis [492],
preserving chromosomal stability [490]. BRCA1 showed
decreased expression in a study involving immortalized prostate
epithelial cells before and after their conversion to tumorigenicity
[493]. Lack of BRCA1 function may impair activation of STAT3
[494]. Inactivation of TP53 by somatic mutations is also
associated to the panel of disruptions which are common for
this ‘‘tumor suppressor’’ [113]. One possible mechanism for gene
Figure 15. A plot showing that restricting our analysis to 29 samples does not have a major negative impact or changes in the
computation of modified statistical complexities.
doi:10.1371/journal.pone.0012262.g015
Figure 14. A region of interest of Figure 12 containing the 29 samples to be used in the analysis. Due to the characteristics of this
microarray dataset and the experiment setting, the Normalized Shannon Entropy correlates well with the established clinical notions of malignancy
(high Gleason patterns). Most Gleason pattern 5 samples (in red) have lower values of Normalized Shannon Entropy than Gleason pattern 3 samples.
doi:10.1371/journal.pone.0012262.g014
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that BRCA1, RASSF1, GSTP1 and EPHB2 promoter
methylation is common in prostate biopsy samples. Mannicia et
al. suggest that the mitochondrial localization of BRCA1 proteins
may be a significant factor in regulating the mitochondrial DNA
damage [5].
SFPQ - (Polypyrimidine tract-binding protein-associated
splicing factor). The most positively correlated gene with the
loss of Normalized Shannon Entropy is SFPQ/PSF (Polypyrimidine
tract-binding protein-associated splicing factor) (Spearman
correlation of 0.7902), a multifaceted nuclear factor [496,497]
which is also a putative regulator of growth factor-stimulated gene
expression [498]. This is extremely interesting as it has been
recently shown that the AR/PSF complex interacts with human
PSA gene and that PSF inhibits AR transcriptional activity [499].
The loss of expression of SFPQ and other proteins that together
regulate androgen receptor-mediated gene transcription [500] (see
also [501,502]) may indicate they have a role not only as a
biomarker of the progression and well as transitions of the disease
to androgen independence. In a study of human labor, Dong et al.,
also showed that SFPQ acts as a Progesterone Receptor
corepressor, thus putatively contributing to the functional
withdrawal of progesterone [503]. We will return to this
particular gene later on the ‘Discussion’ section as new evidence
of its role in nuclear organization has been documented.
CD40 - (TNFRSF5, B-cell surface antigen CD40). The loss
of Normalized Shannon Entropy gives us several markers that indicate a
de-differentiation from a epithelial basal phenotype and an
increasing loss of control of cell cycle regulation (due to
uncoordinated upregulation of CDK4, CDK7, CCNG2 with their
functional partners). This poses the question: What can we observe while
looking at the genes that most positively correlate with the loss of Normalized
Shannon Entropy? We observe, second on the ranking of all samples, a
probe for CD40 (TNFRSF5, B-cell surface antigen CD40),
BX381481 with a Spearman correlation of 0.7616. Loss of CD40
expression has been previously reported in prostate cancer and
it is the object of a study that attempts to establish dendritic cell
genetherapies[504,505,506,507,508,509,510,511,512,513,514,515,
516,517,518,519,520,521,522]. We will continue discussing CD40
in the following subsection in concert with other genes.
Correlations of the genes’ expressions profiles across
samples with the MPR-Statistical Complexity
Another natural question can be asked: Which is the extra
information that we can obtain the by analysing the correlations with the
MPR-Statistical Complexity in this case? As we have discussed before,
and can be appreciated from Figure 14, there is a strong
correlation between the MPR-Statistical Complexity and the value
of the Normalized Shannon Entropy. It appears in prostate cancer, as
in this gene expression dataset, the reduction of Entropy is not the
major factor responsible for the increase in MPR-Statistical Complexity.
Again, it is perhaps better to now look at one of the multiplicative
factors of the statistical complexity measure, the Jensen-Shannon
divergence to the equiprobability distribution, as this is increasing the
MPR-complexity.
CD40. We present more evidence of the case of CD40 as a
biomarker, since a probe for CD40 (BX381481) ranks 6
th (the
Spearman correlation of the probe expression with the Jensen-
Shannon divergence from the equiprobability distribution is 20.5764).
CD40 is a member of the TNF receptor superfamily. Notably, in
56 out of 57 archival prostate cancer samples Palmer et al. have
reported no CD40 expression [518]. However, CD40 expression
was present in normal prostatic acini, so they proposed that
‘‘invasive prostate cancer is a CD40-negative tumour’’ (see the previous
results of Moghaddami et. al. [514]). Matching our observations,
they proposed that CD40 provides ‘‘insight into progression of cancer
from normal epithelium’’; our proposed methodology is revealing this
fact as well. Depletion of CD40 in the tumour microenvironment
may be central in avoiding the action of the immune system [506],
as prostate cancer induces a progressive suppression of the
Figure 16. A scatter plot of Spearman versus Pearson correlation values of the probe expression of 13,188 probes in True et al.’s
prostate cancer dataset with the Normalized Shannon Entropy values of the samples. The identification of probes that best correlate, either
positively or negatively, with the values of the Normalized Shannon Entropy of the samples highlights some of the most important biomarkers in
prostate cancer, like CDKN2C, MAOA, CDK4, CDK7, AMACR, TP53 and BRCA1 (with an upregualtion trend from their normal expression values). The list
includes others that present a downregulation from their normal values, like LMNA, CD40, and SFPQ. These genes are discussed in detail in the
context of current prostate cancer research in the main text. This result has revealed some of the most relevant biomarkers of prostate cancer
progression (AMACR, MAOA, CDK4, TP53, BRCA1, STAT3), and some unexpected new complementary biomarkers (i.e. SFPQ, CD40, STAT3, LMNA,
CD59 etc).
doi:10.1371/journal.pone.0012262.g016
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should be put together in the context of other pieces of information
coming from immunotherapy [508,512,513,516] and phar-
macological studies [507] that warrant serious investigation
towards the design of new and improved clinical studies [508,517].
CD59 molecule, complement regulatory protein. Four
probes for protectin [335,523,524], CD59, with Spearman
correlations with the Jensen-Shannon divergence from the
equiprobable distribution, ranging from 20.61823 to 20.5089,
rank between the 1
st and 39
th position (when we rank genes
according to this correlation in ascending order). CD59 is an
interesting gene as ‘‘a comprehensive investigation of CD59 expression in
prostate cancer has not been conducted yet’’ [524]. Like LMNA (which is
ranked third and will be discussed later) the rank of CD59/
protectin means that these genes progressively loose expression of
these probes. CD59 is expressed in the prostatic epithelium [525]
and in prostasomes [526]; secretory granules which are produced,
stored and released by the glandular epithelial cells of the prostate
[527]. Babiker et al. concluded in [335] that prostasomes (via
expression CD59) contribute to the protection of malignant cells
from complement attack. We now investigate if the ratio of delta-
catenin to CD59 can is a more robust biomarker for non-invasive
prostate cancer detection, particularly after the results presented in
[528]. We also note that CD59 may be also relevant to reveal the
heterogeneous nature of prostate cancer. Its correlation was good,
but is not lower than 20.62, which in our experience, indicates
that we may be dealing with at least two types tumors in this
dataset. Indeed, Xu et al. obtained CD59 mRNA levels were
determined by real-time PCR in matched (tumor/normal)
microdissected tissues from 26 cases and they found that: ‘‘High
rates of CD59 expression were noted in 36% of prostate cancer cases and were
significantly associated with tumor pT stage (P=0.043), Gleason grade
(P=0.013) and earlier biochemical (PSA) relapse in Kaplan-Meier analysis
(P=0.0013). On RNA level, we found an upregulation in 19.2% (five
cases), although the general rate of CD59 transcript was significantly lower in
tumor tissue (P=0.03)’’ [524]. They concluded that: ‘‘CD59 protein is
strongly expressed in 36% of adenocarcinomas of the prostate and and is
associated with disease progression and adverse patient prognosis’’ [524].
Jarvis et al. have previously hypothesized that CD59 expression, in
some cancer cells, may help to regulate the immunological
response, protecting them from the cytolytic activity of
complement [523] (see also [529,530]).
LMNA (Lamin A/C). The third probe in the ranking
corresponds to a LMNA (Lamin A/C), AY528714. Mutations
on LMNA have been linked at 10 different human diseases
[531,532]. LMNA, due to its functions, could be involved in
important cell fate decisions as lamins are involved in the
organization of the functional state (and position) of interphase
chromosome [531]. Lamins are ‘‘scaffolders’’ for the function of
nuclear processes such as chromatin organization, DNA
replication, cellular integrity and transcription [532]. As a
consequence Lamins are involved in several clinical syndromes
[533,534,535]. Among the recent functions attributed to LMNA is
as an intrinsic modulator of ageing within adult stem cells via a
mechanism where LMNA act as signalling receptors in the
nucleus. These observations correspond to Pekovic and
Hutchinson who observed that dysfunction of LMNA leads to
inappropriate activation of self-renewal pathways and initiation of
stress-induced senescense [536]. In lmna-deficient mouse
embryonic fibroblasts (lmna(2/2) MEFs), the loss of
lmna‘‘dramatically affects the micromechanical properties of the cytoplasm’’,
since ‘‘Both the elasticity (stretchiness) and the viscosity (propensity of a
material to flow) of the cytoplasm in Lmna(2/2) MEFs are significantly
reduced’’ [537]. Using ballistic intracellular nanorheology to
evaluate the micromechanical properties of the cytoplasm of
these cells, Lee et al. conclude: ‘‘Together these results show that both the
mechanical properties of the cytoskeleton and cytoskeleton-based processes,
including cell motility, coupled MTOC and nucleus dynamics, and cell
polarization, depend critically on the integrity of the nuclear lamina, which
suggest the existence of a functional mechanical connection between the nucleus
and the cytoskeleton. These results also suggest that cell polarization during cell
migration requires tight mechanical coupling between MTOC and nucleus,
which is mediated by lamin A/C’’ [537] (see also [538,539]). In
addition to these very interesting findings, a functional association
of LMNA and the retinoblastoma protein (pRB) exists. Nitta et al.
have shown that pRB needs to be stabilized by LMNA for
INK4A-mediated cell cycle arrest and that somatic mutations in
LMNA may also have a role in tumor progression [540]. In
mammalian cells, LMNA a) colocalizes with c-FOS at the nuclear
envelope, b) suppresses AP-1 through a direct interaction with c-
FOS and, in LMNA-null cells perinuclear localization of c-FOS is
absent (but it is restored when it is overexpressed, c) LMNA-null
cells have enhanced proliferation [74]. These results obtained by
Ivorra et al. are giving the indication that of yet another
mechanism of cell cycle and transcriptional control mediated by
LMNA [74] (see also [541]). LMNA has also been proposed as an
inhibitor of adipocyte differentiation [542]. Hutchingson et al.
have proposed the alias of ‘‘guardian of the soma’’ for lamins A
and C as they seem to have ‘‘essential functions in protecting cells from
physical damage, as well as in maintaining the function of transcription factors
required for the differentiation of adult stem cells’’ [543].
NF-kappaB regulated genes reveal links to focal adhesion
and ECM-receptor interaction and immune response
disregulation
From our results, we can not completely establish if the
downregulation of CD40 and CD59 are enough to pinpoint an
impaired or abnormal immune response. If we continue the
inspection of the list, the first 20 probes give us more supporting
evidence. The 20 probes correspond to 13 different genes. Five of
these 13 genes have Genome Ontology information annotated as
‘‘defense response’’, the above mentioned CD59 and CD40 as well
as IL4R (interleukin 4 receptor, CR616481), XBP1 (X-box
binding protein 1, AK093842) and HLA-A (major histocompat-
ibility complex class I HLA-A29.1, BU075230). Takahashi et al.
[544] report an inverse correlation between XBP1 expression and
histological differentiation in a series of prostate cancers without
hormonal therapy, the expression of XBP1 was localized in
epithelial and adenocarcinoma cells of the prostate and the
majority of refractory cancer cases exhibited weak XBP1
expression), MST1/STK4 (along with MST2/STK3) act as
inhibitors of endogenous AKT1, a mediator of cell growth and
survival [545].
We can not yet know what reason is behind their joint
downregulation, but another interesting common denominator is
that 12 out of 13 genes share a regulatory motif for NF-kappaB
(according to TRANSFAC, V$NFKB_Q6_01). A putative role for
NF-kappaB in prostate cancer has been reported based on the
observation of the centrality of NFKB on two up- and down-
regulated networks compairing prostate tumors and healthy tissue
[546] and in a larger study by McDonnel et al. [547] (255 core
prostate cancer tissue microarrays from 47 prostatectomy
specimens). Several other researchers are currently investigating
different roles of the NFKB family in prostate cancer
[548,549,550,551,552,553,554,555] and it could be a promising
target for intervention [555,556,557,558,559,560,561,562,563,
564,565,566,567,568,569,570,571]. If we include other genes
following the ranking order, the first 38 genes in the ranking
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(GATHER reports for this list a p-value of 0.0006). Even when we
double the list to the probes that correspond to the first 76 different
genes recognized by GATHER, 58 of them have the regulatory
motif V$NFKB_Q6_01, with p-value=0.003 (ATP6AP2, BCAT1,
BTG2 [572,573,574,575,576,577,578], C14orf123, C18orf45,
CCL2, CD302, CD40 (already discussed), CD59 (already
discussed), CHI3L1, COL16A1, COMMD6, CRABP2, CSRP1,
CTBP2, CTGF (Connective tissue growth factor,
[579,580,581,582]), DES, DMN, DNAJB1, EGF, EMP1, FHL2
[583,584,585,586,587,588], GRIPAP1, GSTM1 [589,590],
HBEGF, IL4R, ITGA3, ITGA7, JUNB [591,592], KIAA0152,
KIAA1191, KIAA1324, KLF6, LAMB2, LMNA (already dis-
cussed), NFATC1, NFKB2, NUDC [593], P4HB, PDK2, PIM1,
PISD, PXN, RAP1B, RNF40, SARA1, SEC61A1, SGTA [594],
SLC12A2, SRD5A2, STAT6 [595,596], TACSTD2, TBX1,
TMED3, VPS39, WDFY3, XBP1 [544], ZAK). This result
indicates that our results support the importance of NFkappa-B
and the huge amount of research effort to understand the role of
the NFkappa-B activity and its potential as a target for
intervention in prostate cancer (File S4).
The group of 58 biomarkers contains one of particular interest,
STAT6. This gene is considered a survival factor in prostate
cancer and a key regulator of the genetic transcriptional program
responsible for progression [595]. STAT6 has been recently linked
to HPN as one of the most robust pair of biomarkers for prostate
cancer using an integrative approach that linked several micro-
array datasets [596].
Focal and cell adhesion modifications can be inferred by
monitoring losses of a group of genes composed by EFG,
Integrins, LAMB2, Paxillin and RAP1B
Analysis using GATHER of this group reveals that six of these
58 genes are in KEGG pathway path:hsa04510, Focal adhesion (EGF,
ITGA3, ITGA7, LAMB2, PXN, RAP1B, p-value,0.0007) and
from these there are three in pathway:hsa045122, ECM-receptor
interaction (ITGA3, ITGA7, LAMB2, p-value,0.005) while four of
these six are also in path:hsa04810: Regulation of actin cytoskeleton,
(EGF, ITGA3, ITGA7, PXN, p-value,0.01).
LAMB2. Alterations of the gene profile of LAMB2 and
CDKN2C/p18(Ink4c), a CDK4 inhibitor, have been reported
on the transition from prostatic intraepithelial neoplasia (PIN) to
prostate cancer [597] (see also [333]).
ITGA7 (integrin, alpha 7) and ITGA3 (integrin, alpha
3). The contribution of the loss of these integrins and the
subsequent derived impairment on cell adhesion has been reported
in several tumours. Ren et al. in [598] report that ‘‘Focal or no
integrin alpha 7 eexpression in human prostate cancer and soft tissue
leiomyosarcoma was associated with a reduction of metastasis-free survival (for
example, for prostate cancer with focal or no expression, 5-year metastasis-free
survival was 32%, 95% CI=24.4% to 40.3%, and for prostate cancer
with at least weak expression, it was 85%, 95% CI=79% to 91%;
p-value,.001)’’.
Discussion
‘‘Any method involving the notion of entropy, the very existence of which
depends on the second law of thermodynamics, will doubtless seem to
many far-fetched, and may repel beginners as obscure and difficult of
comprehension.’’
Willard Gibbs, Graphical Methods in the Thermodynamics of
Fluids, (1873)
Transcriptional vs. Karyotypic Entropy
The changes of the Normalized Shannon Entropy and Statistical
Complexity of the gene expression profile of a cancer cell are
associated with the gradual deterioration of genome transcription-
al information content due to the modification of its structural and
functional integrity during disease progression. Our results clearly
suggest that we can track the cancer cell’s progression by following
observable changes in the Shannon Entropy and, in particular, by
employing the Jensen-Shannon Divergence of the gene expression
profile of a sample to the normal expression profile. We have also
shown if an average expression profile of some state of interest can
be properly defined (i.e. distant metastasis) then the Jensen-Shannon
Divergence can help us to identify which probes best correlate with
these measures resulting in useful biomarkers.
Before any thermodynamical consideration could be discussed,
we note that there is a clear and objective informational perspective
that our study delivers. In this study we have chosen to position
ourselves as the ‘receivers’ of a ‘transcriptional message’. In this
experimental perspective the tumor tissue is the ‘sender’ (the
source of information) and the high-throughput technology (gene
expression microarrays in this case) can be regarded as the
transmission medium (providing noise and distortion). As we
explain in the ‘Materials and Methods’ section, the Shannon Entropy
of a gene expression profile is the average expected surprisal of that
profile understood as a message. The Normalized Shannon Entropy
makes this surprisal an intensive measure and the correlation of the
gene expression patterns across samples with this measure can
deliver useful biomarkers to track the progression of transcriptional
change. After normalization, we have a measure that does not
depend of the number of probes of the high-throughput technology,
although, it obviously does depend on the type of probes used.
We believe that the readers may have already noticed an
apparent paradox. While some researchers understand cancer
progression as a mechanism that increases entropy, we actually
observe a reduction of Normalized Shannon Entropy in this work. This
means that our normalized average expected surprisal, as receivers of the
transcriptional message, is smaller. We must then discuss the
physical meaning of thermodynamic entropy, its current use in
systems biology and cancer research genetics and the informa-
tional measure we use in this paper to clarify these notions in this
context.
In biomedical research there exists a certain consensus among
cancer researchers that genetic instability or ‘‘mutability’’ is a major
critical force of cancer progression, but it is not the only one to
consider. It is clear that the mutational damage of key genes (like
TP53, TERT, BRCA1, RB1, etc.), and the collective damage
inflicted on key DNA repair mechanisms (like Nucleotide-excision
repair and Base-excision repair) collaborate for an increasing
acceleration of the number of genomic changes. Sub-microscopic
alterations of the genome accumulate in cancer progression in an
irreversible way and ‘‘are compounded by the widespread scrambling of the
chromosome structure, and thus the karyotype, found in cells from the great
majority of solid tumours’’ [599]. In Weinberg’s own words [599]: ‘‘we
learned that this chromosomal chaos also contributes this progression forward’’.
This ‘‘chromosomal chaos’’ [600] or ‘‘cancer as a chromosomal disease’’
perspective is viewed by some researchers not as just a side
consequence of mutational damage, but as the main core theme to
understand a number of unexplained issues in cancer progression.
‘‘In sum, cancer is caused by chromosomal disorganization, which increases
karyotypic entropy’’ [601]. Regarding the cancer types studied in this
paper, one particular ‘‘measure of disorder of a system’’, aneuploidy,
has been observed in poorly-differentiated prostate cancer cells
and it is often associated with a more agreessive phenotype
[602,603], increased PSA levels [604,605], and correlate with
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ments are other source of increase in the ‘‘disorder’’ of the genome
organization and they are increasingly being recognized as a major
player in prostate cancer progression [609]. The increase in
‘‘karyotypic complexity’’ and ‘‘extended aneuploidy and heteroploidy’’ may be
already enough to develop a malignant melanoma phenotype, as
the report of Gagos et al. indicate [610]. The observed finding of
aneuploidy in melanoma (also including uveal melanoma) is also
increasingly important due to a number of different independent
observations [247,611,612,613,614,615,616,617,618]. It is in this
context that the word ‘entropy’ has been used.
The magnitude of the ‘‘chromosomal chaos’’ is also evident
from comparative genomic hybridization (CGH) studies which
show significant variations in the copy number of individual
chromosomal segments. ‘Chaos’ is really a very appropriate word to
describe what we observe from CGH data. The genomic changes
are not distributed uniformly at random. ‘Chaos’ has been
described by some researchers as ‘‘a kind of order without any
periodicity’’. Some common changes seem to consistently appear in
several independently arising tumours of the same type, and
sometimes the researchers suggest common links [619]. Our work
has addressed, in part, this question: ‘‘Can we quantify the chaos
observed in the genome from the increasingly available transcriptional data and
relate it to tumour progression?’’ If no commonalities were observed, we
would not have found interesting biomarkers that seem that
strongly correlate with the divergences from normal tissue types.
We know from our results that these commonalities do occur.
We need to go back to basics to explain these evolving concepts
and resolve this apparent paradox. The phrase ‘‘karyotypic entropy’’
has been used in the past to define what is actually a divergence from
the normal chromosome structure and it genomic organization.
This denomination has also been employed by several authors,
notably [601], but it has also been used in at least two other
publications [620,621]. These works have in common the use of
this term to refer to a ‘‘disorder’’, fuelled by the undergraduate
textbooks indoctrination of associating increase of entropy in
natural spontaneous processes with the increase of ‘‘observed
disorder’’ in the system. We propose that the use of a natural
measure of divergence, the Jensen-Shannon divergence, could not only
be a more formal, but also more appropriate modelling approach.
As such, we propose to introduce the term ‘karyotypic divergence’o r
‘karyotypic Jensen-Shannon divergence’ to replace this concept and to
avoid a subjective approach.
Why is it the case that we observe the Normalized Shannon Entropy
of the transcriptional profile decreasing with cancer progression when intuitively
our average expected surprisal (Shannon Entropy) should increase with
progression?
Arieh Ben-Naim in his recent book ‘‘A farewell to Entropy:
Statistical Thermodynamics based on Information’’ [622] comments:‘‘It is
interesting to note that Landsberg (1978) not only contended that disorder is an
ill-defined concept, but actually made the assertion that ‘it is reasonable to
expect ‘disorder’ to be an intensive variable’’’. Ben-Naim also states: ‘‘In
my view, it does not make any difference if you refer to information or to
disorder, as subjective or objective. What matters is that order and disorder
are not well-defined scientific concepts. On the other hand, information is a
well-defined scientific quantity, as much as a point or a line are scientific in
geometry, or mass or charge of a particle are scientific in physics.’’ However,
in a manuscript entitled ‘‘Can Entropy and ‘order’ increase together ?’’
Landberg defines (in an attempt to decouple the notions of order
and entropy), for a thermodynamical system that can be on N
states the ‘disorder’ D(N) to be the Normalized Entropy (which is a
function of N) divided by Boltzmann’s constant [623]. ‘Disorder’
then is an intensive magnitude bounded by 0 and 1, and ‘order’ is
defined as 1-D(N).
While Landberg’s decoupling argument between order and
entropy [623] may still be controversial in Physics, the question is
pertinent for our apparent paradox (the question that motivates
this subsection). Borrowing from the title of his paper we could
now state the central question as ‘‘Can Shannon Entropy increase while
the Normalized Shannon Entropy decrease?’’ The solution of this
apparent paradox is a trick of escapologism, perhaps also
paralleled by what a cancer cell may be experiencing (or
‘‘reacting’’ in response to increased sources of stresses), and it is
worth discussing in this context. Let H[X] be Shannon Entropy for an
ensamble X with N different values. We will now assume, and here
is the trick, that N is not a constant, but a function of time N(t). Let
D(X(N(t))) be the Normalized Shannon Entropy. By definition
D(X(N(t)))=H(X(N(t)))/log2(N(t)). Then, just by taking the time
derivatives it can be shown that the time variation of D(X(N(t)))
can be negative, although the time rate of H[X] can be positive.
_ D D(X(N(t)))=D(X(N(t)))
~½ _ H H(X(N(t)))=H(X(N(t)){k _ N N(t)=(N(t)log2N(t)) 
where k is a constant. The escape to our paradox is ‘‘achieved’’ via
making explicit the time variability of N(t). Landberg explicitly
mentions that biological systems are examples where growth
processes increase N(t), and perhaps the increased diversity in the
transcriptome of a cancer cell during progression is one of such
examples.
This discussion somehow resolves the apparent disassociations
due to language barriers that may exist between the different
disciplines (physics, information theory, molecular biology and
oncology). A biologist may regard a cancer cell as an entity that,
during progression, may ‘‘spread’’ its transcriptomic profile,
including the generation of a large number of novel molecular
species (due to adquired characteristics during its ‘‘devolution’’ from
the normal type). In our informational perspective, this would be
analogous to a situation in which the sender of a message, after
some time, decides to increase the size of the alphabet of
transmitted symbols. Clearly, it is intuitive to think that the
receiver would be in a situation of increased Shannon Entropy.
However, if the receiver is not aware of the new symbols (or is not
able to detect them) and some of the symbols of the previous
alphabet are no longer used, the receiver would now perceive a
reduction of Normalized Shannon Entropy, observing an increasing
order.
We now borrow an illustrative example from Landberg [623],
but we add a twist to this argument for the purpose of illustrating
this discussion. Suppose we have a sender transmitting only two
possible symbols (N=2), and we will assume that we have the
same probability, let’s denote this as (1/2, 1/2). Then the average
expected surprisal (Shannon Entropy),i sH(X)=1, and the Normalized
Shannon Entropy is also equal to one. Assume now that now our
sender starts to transmit using another symbol, so that we now
have theoretical probabilities of (0.5, 0.25, 0.25). Then N=3, and
the average expected surprisal increases to H(X9)=1.5 the Normalized
Shannon Entropy is now 1.5/log2(3)=0.946… (a reduction). This
‘third symbol’ could actually represent a new ‘‘molecular species’’
or a protein isoform that would not be normally expressed in that
tissue type [624], or even something entirely new, product of a
mutational/deletional event. If our hypothetical high-throughput
technology can only be detecting the first two symbols, and
following the conventions we established in the ‘Materials and
Methods’ section, we would be ‘‘observing’’ frequencies of (2/3,1/
3) since the other events would not be detected with our
equipment. As a consequence, the both the log2(2)=1, Shannon
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0.918293. Obviously, we can not count what we can not observe.
As a consequence, a degenerating transcriptional profile that
produces novel molecular species, and at the same time reduces
those which we can not measure with a particular technology,
would look increasingly more ordered.
Exporting entropy, Maxwell Demons and Aquaporins
We envision that physicists may find here a fertile ground to
explore new ideas and attempt novel mathematical formalisms for
cancer progression from the realm of finite-state thermodynamics [625]
and in particular endorevesible processes [626] and endoreversible
thermodynamics [627]. Some molecular alterations would then be
part of the set of revesible processes that could occur in a cancer
cell, while other processes like aneuploidy or gene fusions could be
truly ‘‘irreversible genetic switches’’ associated with cancer progression
[628]. If we assume that the process is slow (i.e. the times required
for significant variations of the transcriptome’s profile is large in
comparison with the cell’s processes time scales), and follwing the
results of Spirkl and Reis [626], it may be possible that we have a
constant entropy production rate exists during cancer progression
leading to Hauptmann’s ‘‘entropic devolution’’ [629]. Hauptmann
sees a malignant tumour as ‘‘a dissipative structure arising within the
thermodynamical open system of the human body’’ that starts when ‘‘a
localized surplus of energy exists and there is no possibility to export entropy.
An energetic overload in most malignant cells is indicated by their abnormally
high phosphorylation state.’’ His perspective, preceeded in part by
Dimitrov [630], Klimek [631,632] and Marinescu and Viculetz
[633] might then fit well an endoreversible thermodynamic
formalism. Hauptmann says in [629] ‘‘I believe that cancer is a special
kind of adaptation to energetic overload, characterized by multiplication and
mutation of genomic DNA (generation of new biomolecules which enhance the
probability of survival under harmful conditions), and by chiral alterations
(reduction of entropy by entrapping energy) leading to abnormal configurated
biomolecules. In this regard the genetic alterations are probably secondary
changes. Cancer serves to dissipate energy in a type of developmental process but
one in which the results are harmful to the whole organism: an entropic
devolution.’’
This thermodynamical perspective is now worth exploring and
we will discuss it in this context. Assuming that a cancer cell is in a
state of ‘‘energy overload’’, without ‘‘the possibility of exporting entropy’’,
could it lead to some type of ‘‘genetic alterations’’? Which key
mechanisms might be impaired? What consequences is this
‘‘system’’ delivering? Could this be another hallmark for oncosystems
indentification?
In 1871, in this book called ‘‘Theory of Heat’’, Maxwell speculated
the idea of ‘‘a being, who can see the individual molecules’’ and who has
enough reactive intelligence to open and close a unique small hole
existing between two communicating vessels (called ‘A’ and ‘B’). An
ideal gas filled both vessels, so that starting at uniform temperature
theintelligent being could observe themolecules and closeand open
the hole accordingly to a mission: ‘‘to allow only the swifter molecules to
pass from A to B, and only the slower ones pass from B to A.’’ The being,
‘‘without expenditure of work raise the temperature of B and lower that of A in
contradiction to the second law of thermodynamics.’’ The ability of the
‘‘being’’ to use observable information about the system to lower the
thermodynamical entropy has motivated many articles in physics
and fuelled the imagination of many since it was originally
introduced by Mawell, and named as ‘‘demon’’ by Thomson three
years later [622]. An excellent collection of articles until 1990
[634,635,636,637,638,639,640,641,642,643,644] was edited by
Leff and Rex [645]. The Maxwell ‘‘demon’’, far from being
‘‘exorcised’’ from Physics, still inspires interesting new perspectives
[634,635,636,637,638,639,640,641,642,643,644,646,647].
In a letter to Peter Guthrie Tait, Maxwell writes about the
‘‘demons’’: ‘‘Is the production of an inequality of temperature their only
occupation? No, for less intelligent demons can produce a difference in pressure
as well as temperature by merely allowing all particles going in one direction
while stopping all those going the other way. This reduces the demon to a valve.
As such value him. Call him no more a demon but a valve like that of the
hydraulic ram, suppose.’’ (from [645], p. 6). Maxwell gives again here
a sign of his brilliant mind, ‘‘degrading’’ the demon to a valve, but
also offering an inspiring perspective to oncosystems research.
Which types of mechanisms exist in biological systems, and
particularly in individual cells, to control these differential values
in key parameters? Could changes of key physical parameters for
metabolic processes of the cytoplasm and cell’s organelles like
temperature, volume, pH or electrochemical potentials be also implicated in
cancer progression?
The influence of temperature may be giving an interesting
working hypothesis for further research. What are the conse-
quences if cancer cells are a different type of open system which
also operates at a different temperature than a normal cell? Butler
et al. have studied p53 and they argue that at temperatures above
37 degrees centigrades wild-type p53 spontaneously loses DNA
binding activity. While folding kinetics do not show important
changes in a range from 5 to 35 degrees C, the unfolding rates
accelerate 10,000-fold. This leads to a somewhat unexpected
mechanism of p53 inactivation. It could be the case that a fraction
of p53 molecules become trapped in misfolded conformations with
each folding-unfolding cycle due to the increased frequency of
cycling. The occurrence of misfolded p53 proteins can lead to
aggregation and subsequent ubiquitination in the cell, leading to
p53 inactivation [648,649]. If a key ‘‘guardian of the genome
integrity’’ [650,651] and its remarkable conformational flexibility
[652] is challenged by an increase of temperature [653], its role in
genotoxic damage and adaptive response (like that of the skin to
UVB damage [654]) may be impaired. The same may occur for
other members of the DNA damage response. An increment in
temperature has already been linked to skin carcinogenesis.
Boukamp et al. report in that [655] ‘‘exposure of immortal human
HaCaT skin keratinocytes (possessing UV-type p53 mutations) to 40 degrees
C reproducibly resulted in tumorigenic conversion and tumorigenicity was stably
maintained after recultivation of the tumors.’’
On the other hand, natural gradients on physical biochemical
properties can also be challenged in a cancer cell. This in turn
derives in metabolic processes running under abnormal paramet-
ric circumstances. It is well-known that compartimentalization, in
biological systems, naturally require the existence of mechanisms
that would keep some key state variables relatively constant, or
within bounds, for normal operation of the metabolic processes.
One example is very illustrative and a case in point. Instead of
demons, holes, or valves, the cell requires pores in its membranes
to allow osmotic regulatory processes, yet it should preclude the
conduction of protons. This is a nanotechnological design problem
not faced by Maxwell, but certainly solved by biological systems
without the need of an ‘‘intelligent being’’ as Mawell cleverly
pointed to Tait in his letter.
This discussion brings us to one of the gene families we have
already discussed in this paper, the aquaporins [184,656,657,
658,659,660,661]. They are considered the primary water
channels of cell membranes [662,663,664,665]. The specific
functions of each member of this family are now being slowly
mapped by several research labs around the world [666]. Their
clinical role in cancer [667,668,669,670,671,672,673,674,
675],obesity [676], malaria [677,678] and other diseases is
emerging [657,679,680,681,682,683,684,685,686,687,688,689].
In [690], our group observed the dowregulation of AQP3 in all
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this dowregulation was also observed for the CNS and Renal cell
lines. AQP3 was relatively upregulated for Leukaemia and Colon
cell-lines (we refer the reader to the Supplementary Material of
[690] for details). Inhibition of AQP3 in prostate cancer cells was
already proposed as a mechanism that increases the sensitivity to
cryotherapy treatment [691].
The aquaporins are not ‘‘an intelligent being’’ in any real sense,
yet they are so formidable selective that they could easily parallel
Maxwell demon’s efficiency in creating the right conditions for the
cell. Wu et al. give us some clues on the role of point mutations in
the AQP1 and how their effective electrostatic proton barrier can
be impaired [692]. The elicitation of the detailed mechanistic
explanation of this extraordinary selectivity is under intense
investigation with a number of techniques, including sophisticated
molecular dyanamics simulations, for an overview of this field see
[665,693,694,695,696,697,698,699,700,701,702,703,704,705,706,
707,708]. One less known feature of aquaporins is that they may
not only channel water, but also carbon dioxide and ammonia
[709,710,711], glycerol [712] and urea and other small solutes
[713] and, very relevant for cancer research, hydrogen peroxide [188].
At least two of members of this family have been observed in the
inner mitochondrial membrane in different tissues. This in turn
may indicate mitochondrial roles for aquapotins in osmotic
swelling induced by apoptotic stimuli [714].
Could it be possible that we can track cancer progression by
looking at some of these ‘‘Maxwell demons’’? We have seen in
Figure 10, that AQP3 has a reduced expression with increased
progression in our melanoma dataset. Cao et al., reported that
ultraviolet radiation induced AQP3 down-regulation in human
karatinocytes; thus AQP3 has become a strong and plausible link
between UV radiation, skin dehydration [186,715] and photoag-
ing [189]. This may indicate an impared function on skin
hydration [184,185,716,717,718,719]. The expression of AQP3,
as well as AQP1, AQP5, and AQP9 seem to be correlated with
melanoma progression, indicating a common pattern of downreg-
ulation from the higher values in normal skin and benign nevi (see
Figure 17).
Does a similar pattern of aquaporin downregulation exist in
prostate cancer? Wang et al. have looked at the expression and
localization of AQP3 in human prostate using cell lines as well as
patient samples. They have observed AQP3 mRNA ‘‘in both normal
and cancerous epithelia of human prostate tissues, but not in the mesenchyme.
In the normal epithelia of the prostate, localization was limited to cell
membranes, particularly the basolateral membranes. However, the expression of
AQP3 protein in the cancer epithelia was not observed on the cell membranes.’’
This finding seems to implicate the subcellular localization of
AQP3 as a possible indicator of a transition to a more malignant
phenotype. Lapointe’s dataset allows us to see the downregulation
of AQP3 and AQP1. A large subgroup of primary prostate tumors
has reduced levels of AQP3 and AQP1 as most of the lymph node
metastasis samples [Figure 18].
Retrodictions, Postdictions, Predictions, Telomeres, non-
coding RNAs and paraspeckles
One critique that we are aware we could receive is that the
current manuscript presents a novel methodology and an
underlying unifying theory based on retrodictions or postdictions.
Indeed we have shown that the use of the Normalized Shannon
Entropy and the Information Theory quantifiers (the M-complexities and
the Jensen-Shannon divergence) allow to monitor cancer progression
and to identify the best biomarkers that correlate with the
transcriptomic changes. Our approach works in a retrodiction way in
that it looks at data already obtained by other studies, but gives a
unifying framework to track cancer progression. For instance, on
True et al’s dataset, our unifying hallmark of cancer gives not only
MAOA, which was already identified in the original publication,
but also AMACR, CD40, CDK4, etc. are very important
biomarkers for prostate cancer. Analogously, the identification of
KLK3/PSA in Lapointe’s dataset is another important retrodic-
tion which shows the power of the method.
In some sense our approach also works in a postdiction way, as it
helps to evaluate the speculation that cancer cells have ‘‘an entropic
devolution’’. Our results show that the variations of Normalized
Shannon Entropy and Jensen-Shannon divergences indeed give measur-
able changes, and that these changes are related to important
biomarkers in the two types of cancer studied in this work.
In addition, we remark that we are literally making hundreds,o r
even thousands of predictions. The results in the ‘Supplementary
Material’ provide this information for the detailed scrutiny of our
peers. We believe that other probes with gene expression patterns
in high correlation with the probes discussed in this paper, and
perhaps less studied by immunohistochemistry and other methods
in the two cancer types studied here, are worth exploring as a
group of biomarkers. These predictions can be tested with further
studies on staging and patient stratification.
A very recent study by Ballal et al. have linked BRCA1 to
telomere length and maintenance and its loss from the telomere in
response to DNA damage [720] (see also [721]). We have
previously mentioned that BRCA1 is a conspiquous biomarker
arising from the analysis of True et al.’s dataset using our methods.
We found this to correlate with a preivous study that showed that
BRCA1 has a reduced expression in immortalized prostate
epithelial cells before and after their conversion to tumorigenicity
[493]. We also mentioned that the knockdown of BRCA1 leads to
anaccumulation of multinucleated cells [492], preserving chromo-
somal stability [490]. Ballal et al. telomeric ChIP assays to detect
Figure 17. Heat map showing the expression of four of the six probes corresponding to aquaporins (AQP1, AQP3, AQP5, and
AQP9) in Haqq et al.’s melanoma dataset. Primary melanaoma samples (annotated in green) and benign nevi (in yellow) show higher
expression values. Primar melanoma (in orange) show a mixed behaviour and metastaic melanoma samples (in red) show in comparision that their
expression is remarkably lower. We highlight the similarity of this finding with Figure 8, in which we have shown the same behaviour for a group of
genes functionally annotated as being involved in cell adhesion, cell-cell communication, tight junction mechanisms and epithelial cell polarity.
Metastatic melanoma samples, in comparison, show remarkably reduced values of the joint expression of these four probes, indicating the possibility
of an impaired function of these highly selective mechanisms.
doi:10.1371/journal.pone.0012262.g017
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BRCA1 from the telomere following DNA damage. Due to the
role of telomeres in maintaining chromosomal stability [722] and
the inverse correlation of telomere length and divergent karyotypes
in prostate cancer cell lines [723,724] (as well as the recognized
role of telomere dysfunction in the induction of apoptosis or
senescence in vivo [725,726,727,728,729,730], increase of muta-
tion rates [731], DNA fragmentation [732], and their relation with
DNA damage signalling [733]), we checked for other probes of
genes involved in telomeric function.
From those which we were able to identify in True et al’s
dataset, we have found a strong high correlation of the expression
of BRCA1 with TERF2/TRF2 (telomeric repeat binding factor 2)
[734] and a negative correlation with the expression pattern of
TERF2IP (telomeric repeat binding factor 2, interacting protein)
[Figure 19].
Finally, one particular type of probes has also caught our
attention, and we would like to refer to them before concluding
this section.
With the denomination of ‘non-coding RNA’ we identify those
RNA molecules which are functional but that are not translated
into proteins. Many microarray chips contain probes that are
annotated as ‘non-protein coding’, indicating that there might be
some valuable expression data that we can also mine for
information. We note that our method, although employing
transcriptomic data, does not limit its application to protein-
coding information, and that the combined use of protein-coding
and non-coding protein probe expression would allow a more
comprehensive view of the transcriptional state of the cell.
Among non-protein coding, microRNAs [735] are gaining
acceptance as key players in several cancers [736,737,738]
(including prostate cancer [739,740]), but the so-called ‘‘long non-
coding RNAs’’ [741] are also gaining a place in the scenario of
cancer biomarkers (see [742], and [743,744,745]). We thus turned
our attention to these probes that have been annotated as ‘‘non-
protein coding’’ and we highlight some of them that have very high
correlation values with the Normalized Shannon Entropy in True et al’s
prostate cancer dataset. In particular, the probes for MALAT1/
MALAT-1 [742,746,747,748,749,750,751,752,753,754,755,756,
757,758] have a very conspiquous position (See Figure 20). They
located very closely to other protein coding biomarkers that have
also lost expression and have been discussed in this work like SFPQ,
CD40, BRCA1, and TP53 (see Figure 16). MALAT1 has been
recently pointed as a biomarker in primary human lobular breast
cancer as a result of an analysis of over 132,000 Roche 454 high-
confidence deep sequencing reads [749]. An international team,
searchingon thousands of novel non-coding transcripts of the breast
cancer transcriptome, has been able to identify more than three
hundred reads corresponding to MALAT1 [749]. This is a non-
coding RNA which was identified in 2003 in non-small cell lung
cancer, was shown to be highly expressed (relative to GAPDH) in
lung, pancreas and prostate, but not in other tissues including
muscle, skin, stomach, bone marrow, saliva, thyroid and adrenal
glands, uterus and fetal liver [758]. MALAT-1, also known as
NEAT2, is considered to be ‘‘extraordinarily conseved for a
noncoding RNA, more so than even XIST’’ [754]. Our results
indicate that the reduction of expression of some non-coding RNAs,
in particular of MALAT-1, and SNORA60 with respect to their
normal expression in prostate, as well as the upregulation of
SNHG8 and SNHG1 should be monitored as useful biomarkers to
track disease progression.
We will now address another non-coding RNA called NEAT1
which, like NEAT2, is also conserved in the mammalian lingeage.
Before we move onto NEAT1, we will first recall a previous result.
We have noted before the conspiquous position of SFPQ/PSF
(Polypyrimidine tract-binding protein-associated splicing factor) in
Figure 18. Heat map and stacked values showing the expression of the probe that correspond to AQP1 and AQP3 in Lapointe et
al’s prostate cancer dataset (Samples ordered by their total average value). Most of the control samples have a positive joint expression
value (in green). A reduction is observed in primary prostate tumor samples (in yellow), with more than one half of the samples now having negative
values. On the rightmost part of the figure, most of the lymph node metastasis samples (in red) have a strong negative total joint expression of these
two biomarkers.
doi:10.1371/journal.pone.0012262.g018
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correlation with the values of the Normalized Shannon Entropy.W e
highlighted before that SFPQ/PSF is a putative regulator of
growth factor-stimulated gene expression [498]. The loss of SFPQ
expression during the progression of prostate cancer may be an
important key to understand this disease or one of its subtypes. We
have also mentioned that the AR/PSF complex interacts with the
PSA gene (perhaps the most well-established prostate cancer
biomarker) and that SFPQ/PSF inhibits AR transcriptional
activity [499]. Kuwahara et al. showed that SFPQ together with
NONO (Non-POU-domain-containing, octamer binding protein)
and PSPC1 (Paraspeckle protein 1 alpha isoform, formerly known
as PSP1) are expressed in mouse Sertoli cells of the testis and form
complexes that function as coregulators of androgen receptor-
mediated transcription [500]. While new research results [759]
link SFPQ and NONO/P54NRB with the RAD51 family of
proteins (largely regarded as another key protector of chromosome
integrity as being involved in homologous recombination DNA
repair), it is perhaps SFPQ and NONO’s co-localization in
paraspeckles that make this group also remarkable [760].
Paraspeckles [760,761,762,763,764,765,766,767,768,769,770,
771,772,773,774,775,776,777] are a novel nuclear compartment,
of approximately 0.2–1 mm in size, discovered in 2002, by Fox et
al. in Dundee Scotland, following the identification of the protein
PSPC1 (AF448795) in the nucleolar proteomics project at
Lamond’s lab which is described well by Fox et al. [777]. Three
years later, Fox, Bond and Lamond showed that NONO and
PSPC1 form a heterodimer that localizes to paraspeckles in an
RNA-dependent manner [773]. Paraspeckles are dynamic struc-
tures, observed in numbers that vary between 10 and 20, that seem
to control gene expression via retention of RNA in the nucleus
[772]. A long noncoding RNA called NEAT1/MEN epsilon/beta
[754,760,762,764,778], that colocalizes with paraspeckles, seems
to be integral to their structure. Depletion of NEAT1 erradicates
paraspeckles and a biochemical analysis by Clemson et al indicates
that the NEAT1 binds with paraspeckle proteins SFPQ/PSF,
P54NRB/NONO and PSPC1. NEAT1 is also known as TncRNA
(trophoblast-derived noncoding RNA) [754,779,780,781,782,
783,784,785,786] and probes for TncRNA exist on this dataset,
We have observed in True et al.’s dataset that there exists a high
correlation between the Normalized Shannon Entropy with the
expression of SFPQ/PSF, P54NRB/NONO, and TncRNA.
Overall, this implies that the disruption of the function of the
paraspeckles is correlated with the increasing signs of deterioration
of normal transcriptomic state of the cells. While a causal
relationship still needs to be proved, we admire the mathematical
elegance of the Normalized Shannon Entropy of the samples, a global
measure of the average expected surprisal of the transcriptome,
which in turn has lead us to consider the dysfunction of the
smallest nuclear body as a putative biomarker of disease
progression. The role of SFPQ/PSF in the control of tumorigen-
esis is under investigation [787] and the information coming from
these studies would need to be integrated with their role, together
with P54NRB/NONO and TncRNA, in paraspeckles if we want
to achieve a better understanding of these mechanisms.
Conclusions
In this contribution we have shown that for the melanoma and
prostate cancer datasets studied, the quantitative changes of
Information Theory measures, Normalized Shannon Entropy, Jensen–
Figure 19. The stacked average gene expression of probes corresponding to BRCA1 and TERF2 (telomeric repeat binding factor 2)
in True et al’s prostate cancer dataset. The first group of samples (1 to 9 in green) correspond to Gleason 3 pattern, indicating that most of the
samples in this group have no significantly reduced expression of this pair of genes. The second group of columns (10 to 21 in yellow) correspond to
Gleason 4 patterns and the last 8 columns (22 to 29 in red) correspond to Gleason 5 samples. A very recent study by Ballal et al. have linked BRCA1, to
telomere length and maintenance and its loss from the telomere in response to DNA damage [720] (see also [721]). There is an increasing trend of
dowregulation, so it would be interesting to evaluate if indeed this pair of proteins could be an early marker of dowregulation useful to evaluate
samples with Gleason pattern 2, or if may constitute a biomarker useful to distinguish a prostate cancer subtype.
doi:10.1371/journal.pone.0012262.g019
Cancer: The Entropic Hallmark
PLoS ONE | www.plosone.org 25 August 2010 | Volume 5 | Issue 8 | e12262Shannon divergence and the novel Statistical Complexity quantifiers
defined here are in high correlation with gene expression changes
of well-established biomarkers associated to cancer progression. In
addition, variations of the basic technique (i.e. a modified form of
statistical complexity) which allows us to better understand the
phenotypic changes observed in these samples which are
associated with the progression and the transitions of the gene
expression profiles. For instance, in a properly defined Statistical
Complexity vs. Entropy plane, on a melanoma dataset first studied in
Ref. [110], samples appear in well differentiated ‘‘clusters’’. These
clusters correlate well with the phonotypic characteristics of normal
skin, nevi, primary and metastatic melanoma. In this ‘‘Complexity vs.
Entropy’’ plane, primary melanomas samples appear ‘‘bridging’’
benign nevi and metastatic melanoma samples. Our results may
also suggest that the evolution of metastatic melanoma leads to at
least two different subtypes.
The Normalized Shannon Entropy of a transcriptional sample profile
is calculated associating the measured expression values of a gene
with the relatively probability of being expressed. We have
observed that, in general, the transcriptomes of tumour progress-
ing cells tend to have lower values of Normalized Shannon Entropy
than normal ones. Given a population of normal cells of a given
tissue type it is then possible to compute useful measure of
divergence of cancer cell profiles from the normal expression
average profile, in terms of Information Theory quantifiers, the
Shannon Eveness normalized entropy and generalized statistical
complexity [788,789,790].
In addition, our observation of the correlation of the statistical
complexity of tumours with its natural progression allows an
unprecedentedwayoffinding biomarkersthat linkswiththe gradual
deterioration of the genome integrity. The proposed methodology
uncovered, for the first time, evidence of the putative role of
impared centrosome cohesion in melanoma progression.
Statistical complexity has then been able to pinpoint otherwise
unrecognized biomarkers in concert with existing ones, reinforcing
the view that ‘‘chromosomal chaos’’ and ‘‘cancer as a chromosomal disease’’
can be a useful guiding principle to understand the molecular
biology of cancer and uncover the timeline of its progression. This is
a powerful method to uncover ‘‘oncosystems’’ instead of ‘‘onco-
genes’’. ‘‘Oncosystems’’ are a highly differentially disregulated set of
genes that, if linked with the molecular ‘‘hallmarks of cancer’’
described in the introduction, and existing databases with putative
common functional genomic annotations, can help to understand
the biological progression pathways that drive the disease.
On one of the prostate cancer dataset studied (obtained from a
previous published study, [44]), we observe a gradual pattern of
reduction of Normalized Shannon Entropy from three well character-
ized tissue types: normal prostate, primary prostate tumours and lymph node
metastases. On a different dataset on prostate cancer (from Ref
[332]), we observe that a group of samples having Gleason
Figure 20. Non-coding RNAs and prostate cancer. We present again a scatter plot of Spearman versus Pearson correlation values of the probe
expression of 13,188 probes in True et al’s prostate cancer dataset with the Normalized Shannon Entropy values of the samples. All blue dots
correspond to one of the probes, but the only difference with Figure 16 is that we have now highlighted the position of s ome probes which have
been annotated as corresponding to ‘‘non-coding RNAs’’. In particular, we highlight those of MALAT1 (Metastasis associated lung adenocarcinoma
transcript 1, (non-protein coding)), SNORA60 (small nucleolar RNA, H/ACA box 60); both increasingly downregulated, SNHG1 (small nucleolar RNA
host gene 1 (non-protein coding)) and SNHG8 (small nucleolar RNA host gene 8 (non-protein coding)). The probes for MALAT1/MALAT-1
[742,746,747,748,749,750,751,752,753,754,755,756,757,758] have a very conspiquous position, which we could judge a priori to be equivalent in
relevance to those of the previously discussed roles of SFPQ, CD40, BRCA1, and TP53 (see Figure 16). MALAT1 has been recently pointed as a
biomarker in primary human lobular breast cancer as a result of an analysis of over 132,000 Roche 454 high-confidence deep sequencing reads.
Within the thousands of novel non-coding transcripts of the breast cancer transcriptome, Guffanti al., identified more than three hundred reads
corresponding to MALAT1 [749]. This non-coding RNA, first identified in 2003 in non-small cell lung cancer, was shown to be highly expressed
(relative to GAPDH) in lung, pancreas and prostate, but not in other tissues including muscle, skin, stomach, bone marrow, saliva, thyroid and adrenal
glands, uterus and fetal liver (see figure four of Ref. [758]). Our results indicate that the reduction of expression of some non-coding RNAs, in
particular of MALAT-1, and SNORA60 with respect to their normal expression in prostate, as well as the upregulation of SNHG8 and SNHG1 should be
monitored as useful biomarkers to track disease staging and progression to a more malignant phenotype. Interestingly enough, a study published in
2006 by Nadminty et al. has shown that KLK3/PSA modulates several genes, reporting a 16.5 fold downregulation of MALAT1 [810]. While these
results have been obtained using the human osteosarcoma cell line SaOS-2, our results indicate that MALAT1 expression in the normal prostate and
in cancer cells could also be considered as a relevant biomarkers to be tested in the future.
doi:10.1371/journal.pone.0012262.g020
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aggressive phenotype) have lower Normalized Shannon Entropy values
than a subset of Gleason pattern 3 (a pattern which is normally
associated to a less aggressive phenotype but which nevertheless is
still of clinical concern). However, a group of samples having
Gleason patterns 3, 4, and 5 is revealed; this mixed cluster has a
mid-range entropy. This is an interesting fact which correlates
with the limitations observed in Ref. [332]. We note the authors’
comment: ‘‘We were unable to identify a cohort of genes that could
distinguish between pattern 4 and 5 cancers with sufficiently high accuracy to
be useful, suggesting a high degree of similarity between these cancer histologies
or substantial molecular heterogeneity in one or both of these groups.’’ Our
results provide a conciliatory middle ground that explains the
perceived clinical usefulness of Gleason pattern classification,
widely used around the world, while at the same time reveals the
reason for the difficulties of obtaining a good transcriptional
signature for the other two patterns [791].
Wehaveseen,throughadetailed discussionofseveralbiomarkers
in three different datasets, that the variation of the gene expression
distributional profile can be characterized via Information Theory
quantifiers. Our study also showed that current established
biomarkers of the two diseases studied seem to correlate with those
that best co-variatewiththesequantifiers.Forinstance,AMACR,in
our second prostate cancer dataset studied, naturally appears as one
of the most correlated genes (in both the Pearson and the Spearman
sense) with the pattern of variation of Entropy of the samples.
Together with MAOA, which is the highlighted gene in True et al.’s
[332] original publication, AMACR is now being recognized as one
of the best biomarkers in primary prostate cancer with approxi-
mately 180 publications dedicated to it in the past five years. We
have also shown that many gene probes that best correlate with the
divergence of the normal tissue profile have been identified as useful
biomarkers (via other accepted validation methods). This said, the
use of other sources of information, like pathway or gene ontology
databases has lead as to the identification of other cell processes that
may be altered.
We have presented a unifying hallmark of cancer, the cancer
cell’s transcriptome changes its Normalized Shannon Entropy (as
measured by high-througput technologies), while it increments its
physical Entropy (via creation of states we might not measure with
our devices). This hallmark allows, via the use of the Jensen-Shannon
divergence, to identify the arrow of time of the process, and helps to
map the phenotypical and molecular hallmarks of cancer as major
converging trends of the transcriptome. The methodology has
produced remarkable postdictions and retrodictions that show that
it can predictively guide biomarker discovery.
Materials and Methods
We refer the reader to the original publications for details of
methods for data collection, but we highlight here some aspects
that are important to understand the data generation process for
the purpose of our analysis.
Lapointe et al.’s dataset (File S1)
Samples were obtrained from radical prostatectomy surgical
procedures. Samples are labelled as ‘‘tumors’’ if they contain at
least 90% of cancerous epithelial cells, and they were considered as
‘‘non-tumor’’ if they contain no tumor epithelium and are from
the noncancerous region of the prostate. The later samples were
labelled ‘‘normals’’ although the authors alert that some may
contain dysplasia. In this dataset, Lapointe et al. have performed a
gene expression profiling by using cDNA microarrays containing
26,260 different human genes (UniGene clusters). Using 50 mgo f
total RNA from prostate samples Cy5-labeled cDNA was
prepared and Cy3-labeled cDNA used 1.5 mg of mRNA common
reference, pooled from 11 human cell lines (see Ref. [792]). The
fluorescence ratios were subsequently normalized by mean
centering genes for each array, a relatively standard procedure.
In addition, to minimize potential print run specific bias, Lapointe
et al. report that ratios were then mean centered for each gene
across all arrays according to Ref. [793]. We have only used the
genes that the authors report in their first figure, 5,153 genes that
have been well measured and have significan variation in some of
the samples. For the other details of their matrials and methods we
refer the readers to the Supporting Notes and the Materials and
Methods section of their original publication [44].
Haqq et al.’s dataset (File S2)
Samples were obtained from nevus volunteers and melanoma
patients and only those samples that have more than 90% of
tumor cells were profiled. The 20,862 cDNAs used (Research
Genetics, Huntsville, AL) represent 19,740 independent loci.
(Unigene build 166).median of ratio values from the experiment
were subjected to linear normalization in nomad (which can be
accessed at http://derisilab.ucsf.edu), log-transformed (base 2),
and filtered for genes where data were present in 80% of
experiments, and where the absolute value of at least one
measurement was .1.
True et al’s dataset (File S3)
In this dataset, samples have information of 15,488 spots per
array, with a total of 7,700 unique cDNAs represented. The samples
were obtained from frozen tissue blocks from 29 radical prostatec-
tomies accessioned and selected to represent Gleason grades 3, 4,
and 5. The samples are ‘‘treatment naı ¨ve’’, meaning that they were
also selected such that their gene expression profile is also and the
absence of any bias that the treatment before prostatectomy. The
frozen sections (8 mm) were cut from optimal cutting temperature
medium blocks and immediately fixed in cold 95% ethanol. Around
5,000 epithelial cells from both histologically benign glands and
cancer glands were separately laser-capture microdissected (LCM).
The authors of the study have also been very careful to include only
one Gleason pattern in each laser-captured cancer sample, following
a process in which the patterns were assessed independently by two
investigators.The matched benign epithelium was captured for each
cancer sample for a total of 121 samples.
An important characteristic of this dataset is the normalization
procedure. For each spot and in each channel (Cy3 and Cy5), True
et al. substracted the median background intensity from the median
foreground intensity, and subsequently the log ratios of cancer
expression to benign expression were computed. These ratios were
obtained by first dividing the background-subtracted intensities
(Prostate Cancer/Benign) and then taking the logarithm base 2. In
the case that the median background intensity was greater than the
median foreground intensity, the spot was considered missing. We
refer to the original publication for the other aspects of imputation,
spot quality and filtering, but, like in Lapointe et al’s study, they also
filter to keep informative (expression ratios of benign versus cancer
should at least be 1.5-fold or greater in at least half of one of the
Gleason groups as one of the selection criteria).
Normalized Shannon Entropy, Jensen-Shannon
Divergence and Statistical Complexity
Shannon Entropy. In many circumstances, experimental
measurements are associated with the accumulation of individual
results which, ultimately, qualitatively and quantitatively
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absence) of a particular result of an individual experimental
measure is called an event. An event which can take one of several
possible values is called a random variable. Analogously, a random event
is an event that can either fail to happen, or happens, as a result of
an experiment. An event is certain if it can not fail to happen and it
is said to be impossible if it can never happen.
Following Andreyev [794], we will define the probability p(x) of
an event x, as the theoretical frequency of the event x about which the
actual frequency occurrence of the event shows a tendency to fluctuate as the
experiment is repeated many times. The Shannon information content
of an event x (or the surprisal of an event x, [795]), is defined as
h(x)~log2
1
p(x)
  
Following McKay [796], an ensamble X is a triple (x,AX,PX),
where x is the value of a random variable, which takes on one of a
set of possible values, AX~fa1,a2,:::,ai,:::,aNg, having probabil-
ities PX~fp1,p2,:::,pNg, with p(x~ai)~pi, pi§0 and X
ai[AX
p(x~ai)~1.
The Shannon Entropy of an ensemble X (also known as the uncertainty
of X), denoted as H[X], is defined to be the average Shannon
information content. It is the average expected surprisal for an infinitely
long series of experiments. We use the theoretical frequencies to
compute this average, and then we have
HX ½  ~{
X N
i~1
pi(x)log2(pi(x))
Suppose that we have a fair dice, the theoretical frequency of an
event ‘the dice shows a three’ is 1/6, (if the dice is assumed fair, the
theoretical frequency is the same for any number from 1 to 6). In
that case a hypothetical experimentalist guessing will have an
average expected surprise of H[X]=log2(6). We note the two
natural bounds that the entropy can have. The Shannon Entropy
of an ensemble X is always greater or equal to zero. It can only be
zero if p(x~ai)~1 for only one of the N elements of
AX~fa1,a2,:::,ai,:::,aNg. On the other hand, the Shannon Entropy
is maximized in the case that p(x~ai)~1=N. This is the so-called
‘‘equiprobable distribution’’, a uniform probability distribution over
the finite set.
Transcriptional Shannon Entropy. Let f
(j)
i the expression
value of probe i (i=1,…, N) on sample j (j=1,…,M). For each
sample j we first normalize the expression values. We interpret
them as the theoretical frequency of a single hybridization event. We
then define a probability distribution function (PDF) over a finite
set as:
P(j)~ p
(j)
i ~
f
(j)
i XN
i~1 f
(j)
i
;i~1,:::,N
8
<
:
9
=
;
j~1,...,M:
The uniform (equiprobably) distribution is defined as
Pe~ pi~
1
N
;i~1,:::,N
  
and the average probability distribution over all M samples as
Pave~ vpiw~
vfiw
XN
i~1 vfiw
;i~1,:::,N
8
<
:
9
=
;
,
with vfiw ~
1
M
XM
j~1 f
(j)
i
Let He~H½Pe ~log2N, then in this paper we always use the
Normalized Shannon Entropy, defined as:
SP (j)   
~{
XN
i~1 p
(j)
i log2p
(j)
i
He
, j~1,...,M
The Jensen-Shannon divergence and the Statistical
complexity measures
Given a probability distribution function over a discrete finite
set, is then straightforward to calculate its Normalized Shannon
Entropy if we have the theoretical frequencies. Several measures of
‘‘complexity’’ of a probability distribution function have been
proposed. In this work we have used Statistical Complexity measures.
All the complexity measures used in this work are the product of
a Normalized Shannon Entropy of the probability distribution function,
and a divergence measure to a reference probability distribution
function. We follow earlier proposals by Lo ´pez-Ruiz, Mancini and
Calbet who first introduced a statistical complexity measure based
on such a product in [797]. The LMC-Statistical Complexity is the
product of the Normalized Shannon Entropy, H[P], times the
disequilibrium, Q[P]; the latter given by the Euclidean distance
from P to Pe, the uniform probability distribution over the
ensemble. In this paper we used a later modification which we
refer as the MPR-Statistical Complexity [43] which replaces the
Euclidean distance between P to Pe by the Jensen-Shannon divergence
[788,798]. The Jensen-Shannon divergence is linked in physics to the
thermodynamic length [799,800,801,802].
We define the MPR-Statistical complexity [790] as:
C(MPR) P(j)   
~HP (j)    :QP (j),Pe
  
,
where QP (j),Pe
  
~Q0Js P(j),Pe
  
, Q0 is a normalization factor, and
Js P(1),P(2)   
is the Jensen-Shannon’s divergence between two probability
density functions P
(1) and P
(2), which in turn is defined as
Js P(1),P(2)   
~H
P(1)zP(2)
2
  
{
HP (1)   
zHP (2)   
2
In this work, in many cases we compute the Jensen-Shannon divergences
of a probability with a probability of reference which is not the
uniform probability distribution over the ensemble. In general, it is
the average over a subset of probability distribution functions which
are consider to be either the ‘‘initial’’ of ‘‘final’’ states of interest. Let
Pave be such an average, then the M-Statistical Complexity of a
probability distribution function P(j), given a Pave of reference, is given by
C(M) P(j)   
~HP (j)    :Js P(j),Pave
  
An illutrative example. In order to discuss a relatively
simple example that can intuitively provide a grasp of the basic
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hypothetical ‘‘gene expression’’ dataset involving four samples
each with the expression of five unique probes corresponding to
five genes (not necessarily different) as follows in Table 3.
One of the quantifiers that we use in this contribution describes
a measure of order for a sample: the Normalized Shannon Entropy also
known as Shannon Evenness Index [803]. This section focuses on this
quantifiers use and importance (refer to the ‘Materials and
Methods’ section to see how this measure is calculated). In Sample
4 all probes have the same expression therefore it has the highest
achievable value of Normalized Shannon Entropy (H=1). The
Normalized Shannon Entropy values for samples 1 and 2 are the
same (H=0.82). Sample 3, which tends to be less peaked and has
the two most significantly expressed genes with the same value, has
a higher value of Normalized Shannon Entropy (H=0.92) (see
Figure 21).
This simple example shows that the Normalized Shannon Entropy
variations of the gene expression profile convey information about
global transcriptomic changes; however, this measure alone is not
enough to characterize the deviations from normal tissue profiles.
For example, assume that Sample 1 is the normal profile of a
particular tissue type. Assume that Sample 3 is the profile of a
cancer cell that originated from that tissue type, the variation of
Normalized Shannon Entropy can be related to this malignant change.
However, as Sample 2 illustrates, Normalized Shannon Entropy is not
enough to let us to measure the variation from a profile and at
least another Information Theory quantifier is needed. We resort to
Statistical Complexity quantifiers, which in turn use the Jensen-Shannon
divergence [798] to provide this complementary dimension [800]
(refer to the ‘Materials and Methods’ section for a mathematical
definition of the Jensen-Shannon divergence).
Figure 21 shows how the Jensen-Shannon divergence helps us to
evaluate the variation between profiles. Samples 1 and 2, as
perhaps intuitively expected, have the largest divergence between
them, their Jensen Shannon divergence is 0.286636 (JS(1,2)=
Table 3. An example dataset to illustrate the principles of
Shannon Entropy and the Information Theory quantifiers used
in this work.
Gene 1 Gene 2 Gene 3 Gene 4 Gene 5
S a m p l e 1 43210 . 1
S a m p l e 2 0 . 1 1234
S a m p l e 3 52513
S a m p l e 4 22222
The matrix is a hypothetical gene expression dataset containing four samples
each consisting of probes for five genes.
doi:10.1371/journal.pone.0012262.t003
Figure 21. Normalized Shannon Entropy values (H) of the samples from Table 3. Sample 4 has the largest attainable value since the expression
of all probes is the same. Samples 1 and 2, which have the same set of expression values, although in different probes, have the same value of
Normalized Shannon Entropy. As a consequence, there is a need for another quantifier of gene expression to address the permutational
indistinguishability of these two expression profiles. The Jensen-Shannon divergence provides a natural alternative (see Table 4).
doi:10.1371/journal.pone.0012262.g021
Table 4. Jensen-Shannon divergence values using the
example introduced in Table 3.
Samples 1 2 3 4
1 0 0.286636 0.077849 0.82685
2 0.286636 0 0.157463 0.082685
3 0.077849 0.157463 0 0.035851
4 0.82685 0.082685 0.035851 0
While samples 1 and 2 have the same Normalized Shannon Entropy, they have
very different gene expression profiles and this is reflected in their mutual
Jensen-Shannon divergence which is 0.286636. The sample with the smallest
divergence to the equiprobability distribution sample 4 is sample 3.
doi:10.1371/journal.pone.0012262.t004
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to Samples 3, and 4, (JS(3,4)=JS(4,3)=0.035851). See Table 4.
Let HP (j)   
be the Normalized Shannon Entropy of a transcriptional
sample profile, then the MPR-Statistical Complexity C(MPR) P(j)   
is
defined as being proportional to the product of the Normalized
Shannon Entropy times the Jensen-Shannon divergence of the profile with
the equiprobable distribution (in the example above the equi-
probable distribution is that of Sample 4). Then we have
C(MPR) P(j)   
~Q0HP (j)    :Js P(j),Pe
  
,
Where Q0 is a normalization factor. Once again, we refer to the
‘Materials and Methods’ sections for the accompanying formal
mathematical presentation. As a consequence, we can plot the
MPR-Statistical Complexity of the samples of our example as a
function of the Normalized Shannon Entropy as can be seen in
Figure 22.
Annotated genes. A full list of gene references in this paper
along with their descriptions from iHOP (http://www.ihop-net.
org/UniPub/iHOP/) can be found in supplementary material
reference File S5.
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